Version 9 9/13/2017  
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 Protocol Version  9 Date: September  13, 201 7 
 
NCI Protocol #: N/A 
 
Local Protocol #:  
(Millennium #X16057)  
 
Title:  
 
Phase II Trial of ixazomib, dexamethasone and rituximab in patients with untreated 
Waldenstrom’s Macroglobulinemia . 
 
Principal Investigator:  
 
[INVESTIGATOR_465751] J. Castillo, MD  
Email: [EMAIL_8912]   
 
Coordinating Center:   
 
Bing Center for Waldenstrom’s Macroglobulinemia  
Dana -Farber Cancer Institute  
[ADDRESS_974067].  
[LOCATION_011], MA [ZIP_CODE]  
 
Co-Investigators:  
 
Steven P. Treon, MD, PhD  
Dana -Farber Cancer Institute  
[ADDRESS_974068].  
[LOCATION_011], MA [ZIP_CODE]  
 
Statistician:   
 
Katherine Kacena , Ph.D.  
[ADDRESS_974069]  
Natick , MA  [ZIP_CODE]  
Tel: [PHONE_14860]  
Email: [EMAIL_13681]   
 
Responsible Nurse Practitioner:   
 
Toni Dubeau , NP 
Bing Center for Waldenstrom’s Macroglobulinemia  
Dana -Farber Cancer Institute  
[ADDRESS_974070].  
[LOCATION_011], MA [ZIP_CODE]  
Tel: [PHONE_14861]  
[Type text] 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Fax: [PHONE_14862]  
Email: toni_dubeau @dfci.harvard.edu   
 
Study Coordinator:  
 
Kirsten Meid  
Bing Center for Waldenstrom’s Macroglobulinemia  
Dana -Farber Cancer Institute  
[ADDRESS_974071].  
[LOCATION_011], MA [ZIP_CODE]  
Tel: [PHONE_8344]  
Fax: [PHONE_14862]  
E-mail: [EMAIL_11332]  
 
 
Responsible Data Manager:  
 
Kirsten Meid  
Bing Center for Waldenstrom’s Macroglobulinemia  
Dana -Farber Cancer Instit ute 
[ADDRESS_974072].  
[LOCATION_011], MA [ZIP_CODE]  
Tel: 617 -632-5598  
Fax: 617 -582-9982  
E-mail: [EMAIL_11332]  
 
 
Agents:  Ixazomib , Rituximab, Dexamethasone  
 
 
This is an investigator -initiated study.  The principal investigator [INVESTIGATOR_465751] J. Castillo, MD   (who 
may also be referred to as the sponsor -investigator), is conducting the study and acting as the 
sponsor.  Therefore, the legal/ethical obligations of the principal investigator [INVESTIGATOR_20531] a sponsor and those of an investigator.  
 
  
IDR in WM Version 9 9/13/2017  Millennium #X16057    
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 SCHEMA  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Induction  
 
Cycles 1 and 2 q4weeks  
Days 1, 8, 15   Dexamethasone, Ixazomib  
 
Cycles 3 -6 q4 weeks  
Days 1, 8, 15   Dexamethasone, Ixazomib  
Day 1         Rituximab  
 
Maintenance  
 
Cycles 1 -6 q8 weeks ± 2 weeks  
Day 1 , 8, 15    Dexamethasone, Ixazomib  
Day 1    , Rituximab  8 weeks ± [ADDRESS_974073] in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  TABLE OF CONTENTS  
LIST OF ABBREVIATIONS AND GLOSSARY OF TERMS  ................................ ................................ ...............  5 
1. OBJECTIVES  ................................ ................................ ................................ ................................ ....................  8 
1.1 Study Design  ................................ ................................ ................................ ................................ .......................  8 
1.2 Primary Objectives  ................................ ................................ ................................ ................................ .............  9 
1.3 Secondary Objectives  ................................ ................................ ................................ ................................ ..........  9 
2. BACKGROUND  ................................ ................................ ................................ ................................ ......................  9 
2.1 Study Agents  ................................ ................................ ................................ ................................ ........................  9 
2.1 Pharmacokinetics and Drug Metabolism ................................ ................................ ................................ ..........  12 
Preclinical Experience  ................................ ................................ ................................ ................................ ............  13 
2.2 Study Disease  ................................ ................................ ................................ ................................ ....................  29 
2.3 Rationale  ................................ ................................ ................................ ................................ ...........................  30 
2.4 Correlativ e Studies Background  ................................ ................................ ................................ .......................  31 
3. PARTICIPANT SELECTION  ................................ ................................ ................................ .............................  32 
3.1 Eligibility Criteria  ................................ ................................ ................................ ................................ .............  32 
3.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ..........  33 
4. REGISTRATION PROCEDURES  ................................ ................................ ................................ ......................  33 
4.1 General Guidelines for DF/HCC and DF/PCC Institutions  ................................ ................................ .........  3334 
4.2 Registration Process  for DF/HCC and DF/PCC Institutions  ................................ ................................ .........  34 
5. TREATMENT PLAN  ................................ ................................ ................................ ................................ ............  34 
5.1 Pre-Medication  ................................ ................................ ................................ ................................ ................  35 
5.2 Agent Administration  ................................ ................................ ................................ ................................ ....... 35 
5.3 General Concomitant Medication and Supportive Care Guidelines  ................................ ................................  39 
5.4 Duration of Therapy  ................................ ................................ ................................ ................................ ..........  40 
5.5 Duration of Follow Up ................................ ................................ ................................ ................................ ...... 40 
5.6 Criteria for Removal from Study  ................................ ................................ ................................ .......................  41 
6. EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS  ................................ .........  41 
6.1 Anticipated toxicities  ................................ ................................ ................................ ................................ .........  41 
6.2 Toxicity Management and Dose Modifications/Delays  ................................ ................................ ....................  [ADDRESS_974074] in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  7.5 Term ination of Treatment and/or Study Participation  ................................ ................................ ......................  64 
8. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ................................ ...............  [ADDRESS_974075] (IRB)  ................................ ................................ .........................  71 
11.4 Reporting to the Food and Drug Administra tion (FDA)  ................................ ................................ .................  [ADDRESS_974076] Complaints  ................................ ................................ ................................ ................................ ........  73 
12. DATA AND SAFETY MONITORING  ................................ ................................ ................................ .............  73 
12.1 Data Reporting  ................................ ................................ ................................ ................................ ...............  73 
12.2 Safety Meetings  ................................ ................................ ................................ ................................ ...............  74 
12.3 Mon itoring  ................................ ................................ ................................ ................................ ......................  74 
13. REGULATORY CONSIDERATIONS  ................................ ................................ ................................ .............  74 
13.1 Protocol Review and Amendments  ................................ ................................ ................................ ..................  74 
13.2 Informed Consent  ................................ ................................ ................................ ................................ ............  75 
13.3 E thics and Good Clinical Practice (GCP)  ................................ ................................ ................................ ...... 75 
13.4 Study Documentation  ................................ ................................ ................................ ................................ ...... 75 
13.5 Records Retention  ................................ ................................ ................................ ................................ ...........  76 
13.6 IND Annual Reports  ................................ ................................ ................................ ................................ ........  76 
14. STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ...............  76 
14.1 Study Design/Endpoints  ................................ ................................ ................................ ................................ .. [ADDRESS_974077] in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  14.5 Exposure to Investigational Material ................................ ................................ ................................ ..............  77 
14.6 Safety Analysis  ................................ ................................ ................................ ................................ ................  77 
14.7 Efficacy Analyses  ................................ ................................ ................................ ................................ ............  77 
14.8 Sample Size/Accrual Rate  ................................ ................................ ................................ ...............................  77 
14.9 Stratification Factors  ................................ ................................ ................................ ................................ ...... 78 
14.10 Analysis of Secondary Endpoints  ................................ ................................ ................................ ..................  78 
14.11 Evaluation of toxicity  ................................ ................................ ................................ ................................ .... 78 
14.12 Evaluation of response  ................................ ................................ ................................ ................................ .. 78 
15. PUBLICATION PLAN  ................................ ................................ ................................ ................................ ....... 78 
16. REFERENCES  ................................ ................................ ................................ ................................ ....................  79 
17. APPENDICES  ................................ ................................ ................................ ................................ .....................  81 
Appendix A: Performance Status Criteria  ................................ ................................ ................................ ............  [ADDRESS_974078] in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  LIST OF ABBREVIATIONS AND GLOSSARY OF TERMS  
 
Abbreviation  Term  
5-HT [ADDRESS_974079] cancer resistance protein  
hCG  beta-human chorionic gonadotropin  
BID bis in die; twice a day  
BM bone marrow  
BSA  body surface area  
BUN  blood urea nitrogen  
BZD  Benzodiazepi[INVESTIGATOR_207078], IV dosing  
CL P plasma clearance  
CL Total total clearance  
Cmax single -dose maximum (peak) concentration   
CNS  central nervous system  
CO [ADDRESS_974080] computed tomography  
Ctrough single -dose end of dosing interval (trough) concentration  
CV cardiovascular  
CYP  cytochrome P [ADDRESS_974081] in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Abbreviation  Term  
DDI drug-drug interaction  
DLT  dose-limiting toxicity  
DME  drug metabolizing enzymes  
DNA  deoxyribonucleic acid  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
EOS  End of Study (visit)  
EOT  End of Treatment (visit)  
EU European Union  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
G-CSF granulocyte colony stimulating factor  
GGT  gamma glutamyl transferase  
GI Gastrointestinal  
GLP  Good Laboratory Practices  
GM-CSF granulocyte macrophage -colony stimulating factor  
GMP  Good Manufacturing Practice  
Hb Hemoglobin  
Hct Hematocrit  
HDPE  high-density polyethylene  
hERG  human ether -à-go-go related gene  
HIV human immunodeficiency virus  
HNSTD  highest nonseverely toxic dose  
IB Investigator’s Brochure  
IC50 concentration producing 50% inhibition  
ICF informed consent form  
ICH International Conference on Harmonisation  
IDR Ixazomib, dexamethasone, rituximab  
IEC independent ethics committee  
IRB institutional review board  
ITT intent -to-treat 
IV intravenous; intravenously  
IVRS  interactive voice response system  
Ki inhibition constant  
KPS Karnofsky Performance Status  
LDH  lactate dehydrogenase  
LFT liver function test(s)  
MedDRA  Medical Dictionary for Regulatory Activities  
Millennium  Millennium Pharmaceuticals, Inc., and  its affiliates  
MRI  magnetic resonance imaging  
IDR in WM Version 9 9/13/2017  Millennium #X16057     
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Abbreviation  Term  
MRU  medical resource utilization  
MTD  maximum tolerated dose  
MUGA  multiple gated acquisition (scan)  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for 
Adverse Events  
NPO  nothing by [CONTACT_207103] (disease progression)  
Pgp P-glycoprotein  
PK pharmacokinetic(s)  
PO per os ; by [CONTACT_1966] (orally)  
PR partial response  
PRO  patient -reported outcome  
PSA prostate -specific antigen  
QD quaque die ; each day; once daily  
QID quater in die;  4 times a day  
QOD  quaque altera die ; every other day  
QOL  quality of life  
QTc rate-corrected QT interval (millisec) of electrocardiograph  
RBC  red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE  serious adverse event  
SC Subcutaneous  
SD stable disease  
SmPC  Summary of Product Characteristics  
t1/2 terminal disposition half -life 
TGI tumor growth inhibition  
Tmax single -dose time to reach maximum (peak) concentration  
[LOCATION_006] [LOCATION_008]  
ULN  upper limit of the normal range  
US [LOCATION_002]  
Vz volume of distribution in the terminal phase  
WBC  white blood cell  
WHO  World Health Organization  
WM Waldenström Macroglobulinemia  
IDR in WM  Millennium #X16057   
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
[ADDRESS_974082] Induction:  
Cycle s [ADDRESS_974083] on ixazomib 4 mg PO and dexamethasone 20 mg  IV or PO on days 1, 8 
and 15, and rituximab 375 mg/m2 IV on day 1 every 28 days . 
Total duration of induction: [ADDRESS_974084] Maintenance:  
Maintenance therapy will start 2 months ± [ADDRESS_974085] on 
ixazomib 4 mg PO  and dexamethasone 20 mg  IV or  PO administered on day s 1, 8 and 15, and 
and rituximab 375 mg/m2 IV administered on day 1  every 2 months for 1 year (6 cycles) . 
Total duration of maintenance: 52 weeks . 
 
Supportive therapy:  
Acyclovir [ADDRESS_974086] dose of ixazomib . 
Famotidine  20 mg PO  (or other gastritis prophylactic medication)  will start on day [ADDRESS_974087] 30 minutes prior to each rituximab infusion . 
 
A Screening visit will be conducted within 30 days  before baseline (baseline being Day 1, Cycle 
1, before study drug administration). At this visit, a medical history will be obtained with 
complete physical examination, vital signs, and an ECOG performance status. A bone marrow 
aspi[INVESTIGATOR_12752], beta-2-microglobulin, serum and protein electrophoresis with quantification 
of immunoglobulins (IgM, IgG, IgA) and immunofixation studies, and computed tomography 
(CT) scans of the chest, abdomen and pelvis will also be conducted at the Screening visit. Bone 
marrow biopsy and CT scans will not be required if collected up to 90 days prior to screening 
visit. MYD88 L265P mutational status will be determined by [CONTACT_715106]. 
CXCR4 mutational status and Fc γRIIIA -158 polymorphisms will be determined b y the Bing 
Center for Waldenström  Macroglobulinemia Laboratory. Clinical laboratory tests including a 
complete blood count plus differential, electrolytes, BUN, creatinine, comprehensive chemistry 
panel, magnesium, total bilirubin, liver function tests, an d serum pregnancy tests for women of 
child -bearing potential will also be performed at the Screening visit.  
 
Patients who meet the eligibility requirements at the Screening visit, and provide written consent, 
will be enrolled in the study and initiated on study treatment. Patients will be evaluated for 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
9 tolerance and response on Day 1 of each cycle for the duratio n of the trial. Patients will be 
eligible to continue therapy as long as they do not demonstrate progressive disease or 
unacceptable toxicity. Modified response criteria updated at the Sixth International Workshop on 
WM (Owen 2013) will be used to assess r esponse, stable disease, and progressive disease. 
Response outcomes to be determined will include: ORR and major response rates (including 
VGPR and CR rates); landmark analysis for 2 and 4 -year PFS; median TTP; median TTNT. The 
final analysis will be under taken when all participants would have completed the maintenance 
phase of the study.  
 
1.2Primary Objectives  
 
• To evaluate the rate of very good partial response (VGPR) or better to IDR in patients 
with untreated WM  
• To evaluate the toxicity profile of IDR in patients with untreated WM  
 
1.3Secondary Objectives  
 
• To evaluate the rate of CR, partial response (PR), minimal response (MR), stable disease 
(SD) and progressive disease (PD)  
• To evaluate the PFS, disease -free survival (DFS), time to progression (TTP), d uration of 
response (DOR) and time to next therapy (TTNT)  
• To evaluate the attainment of response, and depth of response (VGPR or better) and 
expression of MYD88 L265P and CXCR4 -WHIM mutations in WM.  
• To determine changes in MYD88 L265P burden in response to  IDR in patients with WM 
using real -time quantitative PCR.  
• To evaluate the Fc γRIIIA -[ADDRESS_974088] 
in WM.  
 
2.BACKGROUND  
 
2.1Study Agents  
 
2.1.1 Ixazomib  
 
[IP_ADDRESS] Ixazomib  Background  
 
Ixazomib is a next generation, small molecule inhibitor of the 20S proteasome that is under 
development for the treatment of non -hematologic malignancies, lymphoma, multiple myeloma 
(MM), and other plasma cell dyscrasias. Inhibition of the 20S proteasome has been validated as a 
therapeutic target for the treatment of malignancies using VELCADE ® (bortezomib) for 
Injection, Mi llennium Pharmaceuticals’  first-in-class proteasome inhibitor.  
 
In an effort to broaden activity against a wider range of tumor types and increase activity in 
tumor types where VELCADE has shown activity, Millennium has developed the proteasome 
inhibitor, Ixazomib , formulated for both intravenous (IV) and oral (PO) adm inistration. Ixazomib 
is structurally different from VELCADE. MLN2238 refers to the biologically active, boronic 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
10 acid form of the drug substance, Ixazomib . Ixazomib refers to the citrate ester of MLN2238. In 
water or aqueous systems, the equilibrium shifts  from Ixazomib to form MLN2238. All doses 
and concentrations are expressed as the boronic acid, MLN2238.  
 
[IP_ADDRESS] Ixazomib  Toxicology Studies  
 
After PO administration of MLN2238, the exposures that were tolerated in rats were similar to 
those tolerated in dogs, in dicating similar species sensitivity. Additionally, PO administration for 
5 cycles to rats and dogs resulted in higher plasma exposures of MLN2238 on Day 94 than on 
Day 0, indicating accumulation of MLN2238. Dose -limiting toxicity (DLT) in the GLP -
complian t PO toxicology studies up to 5 cycles in duration in rat and dogs was primarily due to 
effects in the gastrointestinal (GI) and lymphoid systems. Additionally, at doses below those 
associated with DLT, alterations in leukocyte and coagulation parameters c onsistent with an 
inflammatory response were seen in both rats and dogs, and neuronal degeneration of the 
sympathetic, dorsal root, and end organ ganglia was seen mainly in dogs (possibly due to higher 
exposures). All of the effects seen in the GLP -complia nt PO toxicology studies in both rats and 
dogs at tolerated doses were reversible/reversing and can be monitored in the clinic with routine 
clinical observations (GI disturbances and opportunistic infections secondary to lymphoid 
depletion), clinical patho logy assessments (inhibition of erythropoiesis, thrombocytopenia, and 
inflammatory leukogram), and neurologic assessment, as are commonly done for patients treated 
with bortezomib. Ixazomib did not cause significant toxicities that have not been previously  
observed after dosing with bortezomib,  and the neurologic lesions in these studies are similar to 
what has been described after treatment with bortezomib and are believed to be the cause of the 
peripheral neuropathy observed in patients treated with borte zomib.  
 
MLN2238 caused embryo -fetal toxicity to pregnant rabbits at a dose of 1 mg/kg (mean Gestation 
Day 19 AUC 0-72hr 
  1280 hr*ng/mL). Embryo -fetal toxicity has been observed in rats and rabbits 
with other proteasome inhibitors, and thus there is the pot ential for similar effects in humans. A 
dose of 0.5 mg/kg (mean Gestation Day 19 AUC 0-72hr 
  910 hr*ng/mL) was considered the no -
observed -effect level (NOEL) for embryo -fetal effects in this study.  
 
MLN2238 was not mutagenic in a GLP -compliant bacterial re verse mutation assay (Ames assay) 
nor was it clastogenic in a GLP -compliant bone marrow micronucleus assay in mice. Therefore, 
MLN2238 is not a genotoxicant.  
 
Ixazomib demonstrates minimal to no absorbance between 290 to 700 nm, and there is no 
absorption maximum in that range. In a quantitative whole body autoradiography (QWBA) 
study, [ 14C] Ixazomib -derived radioactivity was present in melanin -containing tissues (eg, 
pi[INVESTIGATOR_715078]), but the concentrations decreased in a manner similar  to most 
other tissues throughout the study and so a specific association of radioactivity to melanin was 
not obvious. The data indicate that Ixazomib does not represent a photosafety risk.  
 
[IP_ADDRESS] Ixazomib  Preclinical Antitumor Activity  
 
Ixazomib is a next gener ation proteasome inhibitor. Its active form, MLN2238, is a potent , 
reversible, and selective inhibitor of the 
 5 site of the 20S proteasome. MLN2238 inhibits  the 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
11 
5 site 20S proteasome activity in vitro, with a concentration producing IC 50 of 3.4  nM.  Potency 
is reduced roughly 10 -fold versus 
 1 (IC 50 
 31 nM) and 1000 -fold versus  
2 (IC 50 
 3500 
nM).  MLN2238 was also tested for inhibition against a panel of 103  kinases, 18 receptors 
(neurotransmitter, ion channel, brain and gut receptors), and [ADDRESS_974089] cell viability assay . 
 
The iMyc C
/Bcl-XL GEM model of PCM recapi[INVESTIGATOR_715079],  including 
elevation of serum paraprotein, manifestation of malignant plasma cells in bone  marrow, and 
involvement of osteolytic lesions. iMyc C
/Bcl-XL mice of C57BL6/FVB  background develop de 
novo PCM accompanied by [CONTACT_493165].  This model was used  to ass ess the anti -tumor activity 
of bortezomib and MLN2238.  In addition, the anti -tumor  activity of bortezomib and MLN2238 
was evaluated in a disseminated model of PCM in  immunocompromised mice and in an 
intratibial model of PCM in nude mice.  These 2  models uti lized the DP54 -Luc cell line, a 
luciferase -tagged cell line derived from a tumor  originating in an iMyc C
/Bcl-XL transgenic 
mouse.  
 
Study CPPI -09-EF29  
 
Male and female iMyc C
/Bcl-XL mice of the hybrid (B6 
  FVB/N) F 1 background were  
administered bortezomib  at 1.2 mg/kg IV BIW or MLN2238 at 18 mg/kg IV BIW for  6 
consecutive weeks (treatment phase) (n 
  30), with an untreated group as a control.  The doses 
used represent the MTD for each drug in (B6 
  FVB/N) F [ADDRESS_974090] of drug 
treatment on overall survival, spleen weight, and plasma immunoglobulin G2a (IgG2a) levels (a 
marker for myeloma disease). The results of this study showed that IV BIW administra tion of 
MLN2238 at 18 mg/kg and bortezomib at 1.2 mg/kg prolonged overall survival, reduced 
splenomegaly, and attenuated IgG2a levels in the iMyc C
/Bcl-XL GEM model of de novo PCM.  
 
Study CPPI -09-EF26  
 
Female NOD -SCID mice bearing disseminated DP54 -Luc iMy cC
/Bcl-XL PCM were dosed with 
vehicle (5% hydroxypropyl -beta-cyclodextrin [HP -
-CD]) IV BIW, bortezomib at 0.7 mg/kg IV 
BIW, MLN2238 at 11 mg/kg IV BIW, or MLN2238 at 3 mg/kg SC QD.  The doses used 
represent the MTD for each drug and route of administratio n in NOD -SCID mice. A total of 5 
doses were administered in the IV dose groups and a total of 15 doses were administered in the 
SC dose group. Anti -tumor activity was determined by [CONTACT_70849] T/C ratio of the mean total 
photon flux measurement of tumo r burden on Day 20 after inoculation. In addition, cranial suture 
widening was assessed on Day 23 after inoculation in the IV dose groups by [CONTACT_715107] (SSSA) using computed tomography (CT) imaging.  
 
The results of this stud y demonstrated that bortezomib and MLN2238 show anti -tumor activity 
against DP54 -Luc iMyc C
/Bcl-XL PCM. Importantly, IV MLN2238, but not bortezomib, 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
12 significantly reduced osteolytic lesions (widening of cranial sutures) in this model.  
 
Study CPPI -09-EF27  
 
Female nude mice bearing intratibial DP54 -Luc iMyc C
/Bcl-XL PCM were dosed IV BIW with 
vehicle (5% HP -
-CD), bortezomib at 0.8 mg/kg, or MLN2238 at 13 mg/kg for 3 consecutive 
weeks.  Anti-tumor activity was determined by [CONTACT_70849] T/C ratio of the mea n photon flux 
measurement of tumor burden on Day [ADDRESS_974091] intratibial DP54 -Luc iMyc C
/Bcl-XL plasma cell malignancy.  
 
2.1 Pharmacokinetics and D rug Metabolism  
Clinical IV and PO PK data show that ixazomib citrate  (measured as the biologically active 
boronic acid form of ixazomib [MLN2238]) has multi -exponential disposition with a rapid initial 
phase that is largely over by [ADDRESS_974092] time of occurrence of maximum (peak) concentration (T max) of approximately 
0.5 to 2.0 hours and a terminal disposition half -life (t 1/2) after multiple dosing of approximately 5 
to 7 days [1].  Resul ts of a population PK analysis (n = 137) show that there is no relationship 
between body surface area (BSA) or body weight and clearance (CL). Also, based on stochastic 
simulations for fixed dose, exposures are independent of the individual patient’s BSA [ 2]. Based 
on these data, a recommendation was made for fixed dosing in clinical trials. An absolute 
bioavailability of 67% was determined for ixazomib  using the population PK analysis. Please 
refer to the current ixazomib  IB and Safety Management Attachmen t (SMA) for information on 
the PK for IV doses of ixazomib . 
 
Metabolism appears to be the major route of elimination for ixazomib , and urinary excretion of 
the parent drug is negligible (< 5% of dose). In vitro studies indicate that ixazomib  is 
metabolized  by [CONTACT_20550] P450s (CYPs) and non -CYP enzymes/proteins. The rank 
order of relative biotransformation activity of the 5 major human CYP isozymes was 3A4 
(34.2%) > 1A2 (30.7%) > 2D6 (14.7%) > 2C9 (12.1%) > 2C19 (< 1%). Ixazomib  is not an 
inhibitor  of CYPs 1A2, 2C9, 2C19, 2D6, or 3A4 nor a time -dependent inhibitor of CYP3A4/5. 
The potential for ixazomib  treatment to produce drug -drug interactions (DDIs) via CYP 
inhibition is inferred to be low. However, there may be a potential for DDIs with a conco mitant 
strong CYP3A4 or CYP1A2 inhibitor or inducer because of the potential for first -pass 
metabolism when ixazomib  is administered via the PO route and because of the moderate 
contribution of CYP3A4 - and CYP1A2 -mediated metabolism of ixazomib  in human liver 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
13 microsomes. Ixazomib may be a weak substrate of P -glycoprotein (Pgp), breast cancer resistance 
protein (BCRP), and multidrug resistance associated protein (MRP2) efflux pump transporters. 
Ixazomib is not an inhibitor of Pgp, BCRP, and MRP2.  The potential for DDIs with substrates or 
inhibitors of Pgp, BCRP, and MRP2 is, therefore, inferred to be low. Clinical Study C16009 
(Arm 1) with ketoconazole, a strong CYP3A4 inhibitor, showed a 2 -fold increase in area under 
the plasma concentration vers us time curve (AUC) in the presence of ketoconazole. This resulted 
in the continued exclusion of strong CYP3A4 inhibitors in ongoing/planned clinical studies.  
 
Further details on these studies are provided in the IB.  
 
Preclinical Experience  
Please refer to  the current ixazomib Investigator’s Brochure (IB) and Safety Management 
Attachment (SMA).  
 
[IP_ADDRESS]  Clinical  Experience with Ixazomib  
 
Ixazomib has been evaluated as an oral single agent in phase [ADDRESS_974093] included patients 
with advanced solid tumors, l ymphoma, relapse/refractory MM (RRMM), and relapsed or 
refractory light -chain (AL) amyloidosis and demonstrated early signs of activity. Ongoing 
studies continue to investigate both single -agent ixazomib and ixazomib in combination with 
standard treatments . Based on encouraging preliminary data observed in patients with MM 
requiring systemic treatment, 2 phase 3 trials in newly diagnosed MM (NDMM) (C16014) and 
RRMM (C16010) patient populations are currently evaluating ixazomib in combination with 
Revlimid a nd Dexamethasone (RevDex) versus placebo/RevDex. Both trials are combining 
ixazomib at a weekly dose of 4.[ADDRESS_974094] of food, and oral bioavailability. Studies evaluating the safety and 
pharmacokinetic (PK) of ixazomib alone (in Japanese patients) and in combination  with 
lenalidomide and dexamethasone in Asian adult patients (including Japanese patients) with a 
diagnosis of NDMM are ongoing.  
 
As of 27 March 2013, preliminary clinical data is available for a total of 653 patients across 13 
studies. The emerging safety  profile indicates that ixazomib is generally well tolerated. The 
adverse events (AEs) are consistent with the class -based effects of proteasome inhibition and are 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974095] common A E reported among 384 patients treated in the oral (PO) studies 
(47%). Other common AEs reported in the pooled intravenous (IV) and PO safety populations 
include nausea, thrombocytopenia, diarrhea, and vomiting. Rash is also a commonly reported 
treatment -emergent event; however, there is some variety in its characterization and causality 
resulting in different preferred terms to describe it. A high -level term outline of rash events 
includes rashes, eruptions and exanthems NEC; pruritus NEC; erythemas; papulo squamous 
conditions; and exfoliative conditions. The dose escalation phases of most trials reported in the 
IB have now completed enrollment, and gastrointestinal (GI) symptoms were the common dose -
limiting toxicities (DLTs) when the use of prophylactic ant i-emetics was not permitted per 
protocol. In the expansion cohorts or phase 2 cohorts (as per each study), the incidence and 
severity of GI symptoms was mitigated by [CONTACT_20549] 
(MTD)/recommended phase 2 dose (RP2D) (as per each study) and standard clinical usage of 
anti-emetics and/or antidiarrheal medications as deemed appropriate. Prophylactic use of anti -
emetics has not been required as with other agents but (as outlined in Section 6.7 ) has been used 
according to standard  practice and are effective.  
 
The most frequent (at least 20%) treatment -emergent adverse events (TEAEs) reported with the 
PO formulation pooled from single -agent studies (n = 201) irrespective of causality to ixazomib , 
include nausea (53%), fatigue (51%),  diarrhea (44%), thrombocytopenia (34%), vomiting (38%), 
decreased appetite (32%), fever (21%), and anemia (21%). The most frequent (at least 20%) 
TEAEs reported with the PO formulation pooled from combination trials (irrespective of the 
combination) (n = 173), irrespective of causality to ixazomib , include diarrhea (47%), fatigue 
(44%), nausea (38%), peripheral edema (35%), constipation (33%), insomnia (29%), 
thrombocytopenia (28%), anemia (26%), vomiting (26%), neutropenia (25%), back pain (24%), 
pyrexia (23%), peripheral edema (21%, each), fever (20%), cough (20%), hypokalemia (20%), 
neutropenia (20%), and upper respi[INVESTIGATOR_1092] (20%). Overall rash of all grades is 
reported in approximately 50% of patients and is more common when ixazomib  is given in 
combination with lenalidomide where rash is an overlappi[INVESTIGATOR_5171].  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
15 Additional detailed information regarding the clinical experience of ixazomib  may be found in 
the IB, including information on the IV formulation.   
 
As of 27 March 2013, a total of 507 patients with differing malignancies (multiple myeloma , AL 
amyloidosis, non -hematologic cancers, and lymphoma) have been treated in studies evaluating 
the oral ixazomib formulation.  These patients have been treated with different doses  of ixazomib 
either as a single -agent treatment (in 201 patients) or in combination with currently clinically 
available treatments (in 306 patients).  Information regarding the ongoing studies, patient 
populations, and doses investigated is included in Table 1 -1. 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
16 Table  1-1 Clinical studies of Oral Ixazomib  
Trial/  
Population  Description  Doses Investigated  
C16003  
RRMM  
N = 60  PO, TW, single agent  0.24-2.23 mg/m2 TW 
MTD:  2.0 mg/m2 
DLT:  rash, thrombocytopenia  
Closed to enrollment  
C16004  
RRMM  
N = 60  PO, W, single agent  0.24-3.95 mg/m2 W 
MTD:  2.97 mg/m2 
DLT:  rash, nausea, vomiting, diarrhea  
Closed to enrollment  
C16005  
NDMM  
N = 65  PO, W, combination with LenDex 
28-day cycle  1.68-3.95 mg/m2 W 
MTD:  2.97 mg/m2 
DLT:  nausea, vomiting, diarrhea, syncope  
RP2Da:  4.0 mg fixed  (switched to fixed dosing in 
phase 2, equivalent  to 2.23mg/m2) 
Closed to enrollment  
C16006  
NDMM  
N = 20  PO, TW (Arm A - 42 day cycle) and 
W (Arm B - 28 day cycle), 
combination with Melphalan and 
Prednisone  Arm Aa:  3-3.7-mg fixed dose TW  
DLT:  rash, thrombocytopenia, subileus  
Arm Ba:  3-5.5-mg fixed dose, W  
DLT:  Esophageal ulcer nausea, vomiting, 
hematemesis, thrombocytopenia, ileus, 
neurogenic bladder  
MTD = 3.0 mg  
C16007  
RRAL  
N = 27  PO, W, single agent  4-5.5-mg fixed dosea W 
DLT:  thrombocytopenia,  diarrhea, dyspnea, acute 
rise in creatinine, cardiac arrest  
MTD:  4.0  mg W  
 
C16008  
NDMM  
N = 64  PO, TW, combination with LenDex 
21-day cycle  3.0-3.7-mg fixed dosea W 
MTD:  3.0 mg  
Closed to enrollment  
C16009  
Solid tumors, 
Lymphomas  
N = 54  PO, W, single agent  5.5-mg fixed dosea W 
C16010  
RRMM  
N = 200  PO, W, with LenDex versus placebo -
LenDex  4.0 mg W  
C16011  
RRAL  
N = 4  PO, W, with Dex versus physician’s 
choice of a Dex -based regimen  4.0 mg W  
C16013  
RRMM  
N = 9  PO, W, with LenDex  4.0 mg W  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
17 Table  1-1 Clinical studies of Oral Ixazomib  
Trial/  
Population  Description  Doses Investigated  
C16014  
Symptomatic 
MM 
N=701  PO, combination with LenDex  ixazomib 4.0 mg or matching placebo on Days 1, 
8, and 15, plus Len 25  mg on Days 1 -21 (10 mg if 
low creatinine clearance, with escalation to 15  mg 
if tolerated) and Dex 40  mg (or 20  mg if >75 
years old) on Days 1, 8, 15, and 22  
C16015  
Symptomatic 
MM with 
normal renal 
function or 
severe renal 
impairment  
N=28  PO, combination with Dex  Part A: ixazomib  3.0 mg on Day 1  
Part B: ixazomib  4.0 mg on Days 1, 8, and 15, 
plus Dex 40 mg (or 20  mg if >75  years old) on 
Days 1, 8, 15 and 22 of a 28 -day cycle  
 
C16017  
RR follicular 
lymphoma  
N=58  PO, W  4.0, 5.3, and 7.0 mg, W  
Treatment at RP2D once determined.  
 
C16018  
Advanced 
solid tumors 
or 
hematologic 
malignancies 
with varying 
degrees of 
liver 
dysfunction  
N=45  Part A: PO, Day 1 of 15 -day cycle  
Part B: PO, W  1.5 mg (severe hepatic impairment), 2.3 mg 
(moderate hepatic impairment), or 4.0 mg (normal 
hepatic function)  
 
TB-
MC010034  
RRMM  
N = 10  PO, W  4.0 mg, W  
Single agent: 4.[ADDRESS_974096]  
Abbreviations:   RRAL = Relapsed and/or refractory Primary systemic light chain (AL) amyloidosis; BSA = 
body surface area; Dex=dexamethasone; DLT = dose -limiting toxicity; IV = intravenously; LenDex = 
lenalidomide plus dexamethasone; MTD = maximum tolerated dose; NDMM = newly diagnosed multiple 
myeloma; PO = orally; RR= relapsed and/or refractory; RRAL= relapsed and/or refractory systemic light 
chain amyloidosis RRMM = relapsed and/or refractory multiple myeloma; TBD = to be determined; TW 
= twice weekly; W = weekly; RP2D = recommended phase 2 dose.  
Note that blinded data from pi[INVESTIGATOR_20533] C16010 and C16011 are not included.   
a Approximate BSA and fixed dosing equivalence:  3 mg~ equivalent to 1.68 mg/m2 BSA dosing; 4.0 mg ~ 
equivalent to 2.23 mg/m2 BSA dosing; and 5.5 mg~ equivalent to 2.97 mg/m2 BSA dosing.  
 
[IP_ADDRESS]  Clinical Experience with Ixazomib as Monotherapy  
  
The C16003 study was a phase 1 study in adult patients with relapsed and/or refractory MM who 
had received at least [ADDRESS_974097] include Velcade, thalidomide or 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
18 lenalidomide) and steroids. This study enrolled 60 out of 63 planned part icipants and is closed to 
accrual. Ixazomib was administered twice weekly on days 1, 4, 8 and 11 of a 21 -day cycle and 
underwent dose escalation from 0.24 mg/m2 to 2.23 mg/m2. The MTD for twice weekly 
ixazomib was determined at 2.0 mg/m2.  
 
The C16004 study  was a phase 1 study in adult patients with relapsed and/or refractory MM who 
had received at least [ADDRESS_974098] include Velcade, thalidomide or 
lenalidomide) and steroids. This study enrolled 60 out of 70 planned participants and is closed to 
accrual. Ixazomib was administered once weekly on days 1, 8 and 15 of a 28 -day cycle with dose 
escalation from 0.24 mg/m2 to 3.95 mg/m2. The MTD for weekly ixazomib was determined at 
2.97 mg/m2.  
 
The C16009 study is an ongoing phase [ADDRESS_974099]. There are four arms evaluating ixazomib at different dosages and in combination 
with ketoconazole and rifampin. T he study has enrolled 57 out of 90 planned participants.  
 
[IP_ADDRESS]  Experience with Ixazomib  in Combination with Lenalidomide and Dexamethasone  
 
The C16005 study is a phase 1/2 study in adult patients with newly diagnosed MM. The 
objectives of the phase 1 component are safety, MTD and inform RP2D. The objective of the 
phase 2 component is efficacy. Ixazomib is administered once weekly on days 1, 8 and 15 with 
dose escalation from 1.68 mg/m2 to 3.95 mg/m2. Ixazomib was administered in combination 
with dexame thasone 40 mg PO on days 1, 8, 15 and 22, and lenalidomide 25 mg PO on days 1 -
21 of 28 -day cycles for 12 cycles. This is followed by [CONTACT_715108] 1, 8 and 15 every 28 days until disease progression or unacceptable toxicity. The  MTD of 
ixazomib was 2.97 mg/m2 and the RP2D is a fixed dose of 4.0 mg (approximate equivalent to 
2.23 mg/m2) with full -dose lenalidomide and dexamethasone. This study enrolled 65 participant s 
and is currently closed to accrual.  
 
[IP_ADDRESS]  Dose Rationale  
 
After ora l dosing, MLN2238 is rapi[INVESTIGATOR_19627] a median T max of 1 hour. The observed 
range for the terminal half -life after multiple doses is 2.1 to 11.3 days. Dose proportionality has 
been observed for doses between 0.48 and 3.95 mg/m 2 (0.8-8.9 actual adminis tered dose range) 
of Ixazomib. The 2 -fold increase in AUC observed in the presence of ketoconazole, a strong 
inhibitor of CYP3A (Study C16009), resulted in the continued exclusion of strong CYP3A4 
inhibitors in ongoing/planned studies.  
 
Pharmacokinetic pa rameters for MLN2238 co -administered with lenalidomide and 
dexamethasone (Studies C16005 and C16008), or melphalan and prednisone (Study C16006), 
appear to be similar to those observed when Ixazomib is administered as a single agent. This 
suggests that the re is no readily apparent effect of co -administration of lenalidomide and 
dexamethasone, or melphalan and prednisone, on the clinical PK of MLN2238. Likewise, no 
significant alterations in the disposition of MLN2238 have been noted between patients with 
different malignancies.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
19  
Following either oral administration of ixazomib, maximal 20S proteasome inhibition in blood is 
observed shortly after dosing, mirroring the obtainment of maximum plasma concentrations of 
MLN2238. Maximum inhibition of 20S proteasome  activity is dose dependent with mean values 
approaching 70% to 80% in some of the higher dosing cohorts examined. With the exception of 
some of the higher dosing cohorts studied, prolonged 20S proteasome inhibition (> 96 hours) by 
[CONTACT_715109] . These findings are consistent with MLN2238 being a reversible 
proteasome inhibitor.  
 
A population PK analysis has been performed using preliminary PK data from 137 patients 
treated with IV and PO Ixazomib as a single agent across 4 ongoing, phase 1 studi es intensive 
PK sampling). Patients with solid tumors, lymphoma, or MM were administered Ixazomib via IV 
or PO routes using BSA -based dosing on a twice weekly (Days 1, 4, 8, and 11; 21 -day cycle) or 
weekly (Days 1, 8, and 15; 28 -day cycle) schedule. Effect s of age, body weight, BSA, sex, 
creatinine clearance, ALT, AST, and bilirubin were not significant on the CL of Ixazomib on the 
basis of a univariate analysis (p < 0.05). Because MLN2238 was dosed on the basis of BSA in 
the early phase [ADDRESS_974100] to see if any of the body size covariates 
(weight or BSA) were significant on CL or V2. On the basis of the univariate testing, neither 
weight nor BSA was significant on CL or V2 suggesting that interpatient variability in BSA does 
not contribute to MLN2238 PK variability.  
 
The lack of a discernible relationship between BSA and Ixazomib clearance over a relatively 
wide BSA range (1.4 -2.6 m 2) indicates that total systemic exposure (AUC) following fixed 
dosing should be independent of the  individual patient’s BSA. Therefore, BSA is not expected to 
affect C max or AUC after IV or oral dosing, and thus fixed dosing is appropriate for both oral and 
IV routes of administration. The clinical development of Ixazomib has therefore transitioned 
from the use of BSA -based dosing to fixed dosing in all recently initiated phase 1/2 studies 
(Studies C16005 phase 2, C16007, C16008, and C16009). Accordingly, the starting dose of 
Ixazomib in the proposed phase 3 study in relapsed/refractory multiple myeloma  is a fixed dose 
of 4.0 mg, on the basis of the recommended dose of 2.23 mg/m 2 (using mean patient BSA of 1.86 
m2 from the 2208 patients with MM in VELCADE clinical studies for conversion to a fixed 
dose). Also, no relationship between creatinine clearance  and CL was observed in patients with a 
wide range of renal function (creatinine clearance range: 21.9 -236.1 mL/min) as shown in So, 
starting dose adjustment is not required in patients with mild (60 -90 mL/min) and moderate (30 -
60 mL/min) renal impairment in clinical studies.  
 
[IP_ADDRESS]  Overview of the Oral Formulation of ixazomib  
 
The emerging safety profile indicates that ixazomib is generally well tolerated.  The adverse 
events (AEs) are consistent with the class -based effects of proteasome inhibition and are similar 
to what has been previously reported with VELCADE though the sev erity of some, for example 
peripheral neuropathy, is less.  While some of these potential toxicities may be severe, they can 
be managed by [CONTACT_20548], or, as needed, dose 
modification or discontinuation.   
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
20 In the 4 ongoing studies (C16003, C16004, C16007, and C16009) investigating single -agent oral 
ixazomib in patients with differing malignancies (multiple myeloma, AL amyloidosis, 
nonhematologic cancers, and lymphoma), a total of [ADDRESS_974101] frequent (at least 10%) AEs occurring in the pooled 
safety population from single -agent oral ixazomib Studies (C16003 , C16004, C16007, and 
C16009) is shown in Table [ADDRESS_974102] Common (At Least 10% of Total) Treatment -Emergent Adverse 
Events in Oral Single -Agent Studies  
Primary System Organ Class  
      Preferred Term  Primary System Organ Class  
      Preferr ed Term  
Subjects with at Least One Adverse Event  Subjects with at Least One Adverse Event  
Gastrointestinal disorders  Gastrointestinal disorders  
 Nausea   Nausea  
 Diarrhoea   Diarrhoea  
 Vomiting   Vomiting  
 Constipation   Constipation  
 Abdominal pain   Abdominal pain  
General disorders and 
administration site 
conditions  General disorders and administration site conditions  
 Fatigue   Fatigue  
 Pyrexia   Pyrexia  
 Oedema peripheral   Oedema peripheral  
 Asthenia   Asthenia  
Nervous system disorders  Nervous system disorders  
 Headache   Headache  
 Dizziness   Dizziness  
 Neuropathy peripheral   Neuropathy peripheral  
Metabolism and nutrition disorders  Metabolism and nutrition disorders  
 Decreased appetite   Decreased appetite  
 Dehydration   Dehydration  
Blood and lymphatic system disorders  Blood and lymphatic system disorders  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974103] Common (At Least 10% of Total) Treatment -Emergent Adverse 
Events in Oral Single -Agent Studies  
Primary System Organ Class  
      Preferred Term  Primary System Organ Class  
      Preferr ed Term  
 Thrombocytopenia   Thrombocytopenia  
 Anaemia   Anaemia  
 Neutropenia   Neutropenia  
 Lymphopenia   Lymphopenia  
Skin and subcutaneous tissue disorders  Skin and subcutaneous tissue disorders  
 Rash maculara  Rash maculara 
Musculoskeletal and connective 
tissue disorders  Musculoskeletal and connective tissue disorders  
 Back pain   Back pain  
 Arthralgia   Arthralgia  
Respi[INVESTIGATOR_696], thoracic and mediastinal 
disorders  Respi[INVESTIGATOR_696], thoracic and mediastinal disorders  
 Cough   Cough  
 Dyspnoea   Dyspnoea  
Infections and infestations  Infections and infestations  
 Upper respi[INVESTIGATOR_715080]:  I xazomib  Investigator’s 
Brochure Edition 7  
Abbreviations:  MedDRA = 
Medical Dictionary for Regulatory 
Activities, version 15.0.  
Subject Incidence:  A subject counts 
once for each preferred term.  
Percentages use the number of 
treated subjects as the denominator.  
a Note that rash maculopapular and rash 
macular repr esent the [ADDRESS_974104] common terms 
used to describe rash.  Source:  I xazomib  Investigator’s Brochure Edition 7  
Abbreviations:  MedDRA = Medical Dictionary for Regulatory 
Activities, version 15.0.  
Subject Incidence:  A subject counts once for each preferred term.   
Percentages use the number of treated subjects as the 
denominator.  
a Note that rash maculopapular and rash macular represent the [ADDRESS_974105] Common (At Least 
10% of Total) Treatment -Emergent 
Adverse Event s in Oral Single -Agent 
Studies  Table [ADDRESS_974106] Common (At Least 10% of Total) Treatment -
Emergent Adverse Events in Oral Single -Agent Studies  
Primary System Organ Class  
      Preferred Term  Primary System Organ Class  
 Preferred  Term  
Subjects with at Least One Adverse Event  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974107] frequent (at least 10%) AEs occurring in the pooled safety population from Studies 
C16005, C16006, C16008, and C16013 are shown for all grades (Table 1 -3).  Note that in 
combination trials, related is defined as related to any study drug in the combination regimen.  
 
 
Table [ADDRESS_974108] Common (At Leas t 10% of Total) Treatment -Emergent Adverse 
Events in Oral Combination Studies  
Primary System Organ Class  
      Preferred Term  Total Oral Combo Agent  
(5/6/8/13)  
n = 173  
n (%)  
Subjects with at Least One Adverse Event  163 (94)  
Gastrointestinal disorders  139 (80)  
 Nausea  65 (38)  
 Diarrhoea  81 (47)  
 Vomiting  51 (29)  
 Constipation  57 (33)  
General disorders and administration site 
conditions  132 (76)  
 Fatigue  76 (44)  
 Pyrexia  39 (23)  
 Oedema peripheral  61 (35)  
 Asthenia  20 (12)  
Nervous system disorders  115 (66)  
 Headache  28 (16)  
 Dizziness  34 (20)  
 Neuropathy peripheral  45 (26)  
Metabolism and nutrition disorders  91 (53)  
 Decreased appetite  25 (14)  
 Hypokalaemia  34 (20)  
Blood and lymphatic system disorders  88 (51)  
 Thrombocytopenia  49 (28) 
 Anaemia  45 (26)  
 Neutropenia  43 (25)  
 Lymphopenia  20 (12)  
Skin and subcutaneous tissue disorders  102 (59)  
 Rash maculopapulara 29 (17)  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974109] Common (At Leas t 10% of Total) Treatment -Emergent Adverse 
Events in Oral Combination Studies  
Primary System Organ Class  
      Preferred Term  Total Oral Combo Agent  
(5/6/8/13)  
n = 173  
n (%)  
 Rash maculara 22 (13)  
Musculoskeletal and connective tissue 
disorders  99 (57)  
 Back pain  42 (24)  
 Pain in  extremity  31 (18)  
 Arthralgia  22 (13)  
Respi[INVESTIGATOR_696], thoracic and mediastinal 
disorders  80 (46)  
 Cough  36 (21)  
 Dyspnoea  26 (15)  
Infections and infestations  92 (53)  
 Upper respi[INVESTIGATOR_1092]  35 (20)  
Psychiatric disorders  73 (42)  
 Insomnia  50 (29)  
Source:  Ixazomib  Investigator’s Brochure Edition 7  
Abbreviations:  MedDRA = Medical Dictionary for Regulatory Activities, version 15.0.  
Subject Incidence:  A subject counts once for each preferred term.  Percentages use the number of treated 
subjects as the denominator.  
Data from ongoing blinded pi[INVESTIGATOR_6518] (C16010) are not included.  
a Note that rash maculopapular and rash macular represent the [ADDRESS_974110] a 50% reduction in disease burden in some patients and prolonged disease stabilization  
in others across all ongoing trials. The antitumor activity has been seen with single -agent ixazomib , 
when combined with established therapi[INVESTIGATOR_014], and across the malignancies studied (advanced solid 
tumors [6], non -Hodgkin’s disease, Hodgkin’s disease [7], r elapsed and/or refractory multiple 
myeloma [RRMM; 8, 9], relapsed or refractory systemic light chain amyloidosis [RRAL; 10], and 
newly diagnosed multiple myeloma [NDMM; 11 -13]) to date.  
 
Though additional data are needed to characterize the clinical benefit of this drug, the emerging 
data supports the ongoing development of ixazomib . 
 
 
[IP_ADDRESS]  Relapsed and/or Refractory Multiple Myeloma  
 
The early development of ixazomib  in patients with RRMM inv olves 2 studies (C16003 and 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
24 C16004) with similar objectives, but each investigated [ADDRESS_974111] -in-class proteasome inhibitor, VELCADE.  
Study C16003 is an open -label, dose escalation, phase 1 study of ixazomib  dosing on a twice -
weekly schedule on Days 1, 4, 8, and 11 of a 21 -day cycle in adult patients with RRMM.(11, 12)  
Study C16004 is an open -label, dose escalation, phase 1 study of ixazomib  dosing on a weekly 
schedule on Days 1, 8, and 15 of a 28 -day cycle in adults patients with RRMM.(13, 14, 15)  Both 
studies have now completed enrollment.  The DLTs in Study C16003 were rash macular and 
thrombocytopenia and the DLTs in C16004 were nausea, diarrhea, vomiting, and erythema 
multiforme.  
In the dose escalation com ponent of both studies, patients had multiple myeloma that had 
relapsed following at least [ADDRESS_974112] included bortezomib, thalidomide 
(or lenalidomide), and corticosteroids.  In both studies, when the MTD was established, cohorts 
of patients representing the heterogeneous patient population currently seen in clinical practice 
were to be enrolled into [ADDRESS_974113] that ixazomib  has 
anti-tumor activity in heavily pretreated MM patients, with durable responses/disease control, 
and is generally well tolerated. Please  refer to the ixazomib  IB and SMA for further information.  
 
[IP_ADDRESS]  Newly Diagnosed Multiple Myeloma (NDMM)  
 
Multiple research paths are being explored in patients with NDMM with a focus on evaluating 
ixazomib in combination with agents commonly used across treatment settings.  The 
development of ixazomib in combination with lenalidomide with dexamethasone (LenDe x) in 
patients with NDMM who are transplant eligible or ineligible involves 2 studies (C16005 and 
C16008) with similar study designs except for a few key differences, namely the schedules of 
ixazomib and dexamethasone.  Ixazomib is also being evaluated in combination with melphalan 
and prednisone (MP) for patients who are not transplant eligible due to age or coexisting 
morbidity (in Study C16006).  
 
All 3 studies are phase 1/2, with phase 1 focusing on safety and phase 2 on efficacy (and further 
characteri zation of safety).  Please refer to the ixazomib IB and SMA for further information.  
 
[IP_ADDRESS]  Clinical Trial Experience Using the Intravenous Formulation of ixazomib  
 
See the IB for descriptions of the 2 studies that investigated IV ixazomib in advanced solid 
tumors and advanced lymphoma (Studies C16001 and C16002, respectively).  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
25 [IP_ADDRESS]  Potential Risks and Benefits  
 
Please refer to the current ixazomib  IB and SMA.  
The clinical benefit of ixazomib continues to be studied in a comprehensive and global 
development plan that involves studies sponsored by [CONTACT_20555].  Ixazomib appears to show 
early signs of anti -tumor activity as evidenced by [CONTACT_2669] 50% reduction in disease burden in 
some patients, including patients that have been heavily pretreated as well as those wit h newly 
diagnosed MM, and prolongs stabilization of the underlying disease in other patients across all 
ongoing trials.  The preliminary findings are favorable when considering historical and currently 
available therapi[INVESTIGATOR_715081].  Though additional data are needed to 
characterize the clinical benefit of this drug, the emerging data supports expanded development 
of ixazomib for the treatment of patients with advanced malignancy.  
This study will be conducted in compliance with t he protocol, good clinical practice (GCP), 
applicable regulatory requirements, and International Conference on Harmonisation 
(ICH) guidelines.  
 
2.1.2  Rituximab  
 
[IP_ADDRESS]  Description of Rituximab  
 
Rituximab is a genetically engineered chimeric murine/human monoclonal an tibody directed 
against the CD20 cell surface antigen. The antibody is an IgG kappa immunoglobulin 
containing murine light - and heavy -chain variable region sequences and human constant region 
sequences. Rituximab is a composed of two heavy chains of 451 am ino acids and two light 
chains of 213 amino acids (based on cDNA analysis) and has an approximate molecular weight 
of 145 kD. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. The 
chimeric anti -CD20 antibody is produced by [CONTACT_715110] (Chinese Hamster ovary) 
suspension culture in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not 
detectable in the final product. Rituximab is purified by [CONTACT_715111]. The purification process includes specific viral inactivation and removal 
procedures.  
 
Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death has 
been reported in some patients with hematologic malignancies treated with rituximab.  The 
majority o f patients received rituximab in combination with chemotherapy.  The median time to 
the diagnosis of hepatitis was approximately [ADDRESS_974114] dose.  
 
[IP_ADDRESS]  Immunologic Events  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
26 Rituximab induced B -cell depletion occurred in 70 to 80% of patients, and was associated with 
decreased serum immunoglobulins in a minority of patients. The incidence of infection does not 
appear to be increased. During the treatment period, 50 patients in the pi[INVESTIGATOR_715082] 68 
infectious events; 6 (9%) were grade 3 in severity, and none were Grade 4 events. Of the 6 
serious infectious events, none were associated with neutropenia. The serious bacterial events 
included sepsis due to Listeria (n=1), staphyloc occal bacteremia (n=1), and polymicrobial sepsis 
(n=1). In the post -treatment period ([ADDRESS_974115] dose), bacterial 
infections included sepsis (n=1); significant viral infections included herpes simplex infections 
(n=2) and herpe s zoster (n=3). The following immune serious adverse events have been 
reported to occur rarely (<0.1%) in patients following completion of rituximab infusions: 
arthritis, disorders of blood vessels (vasculitis, serum sickness and lupus -like syndrome), lung  
disorders including pleuritis and scarring of the lung (bronchiolitis obliterans), eye disorders 
(uveitis and optic neuritis), and severe bullous skin reactions (including toxic epi[INVESTIGATOR_715083]) that may result in fatal outcomes. Patien ts may have these symptoms 
alone or in combination with rash and polyarthritis.  
 
Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death has 
been reported in some patients with hematologic malignancies treated with rituxi mab.  The 
majority of patients received rituximab in combination with chemotherapy.  The median time to 
the diagnosis of hepatitis was approximately [ADDRESS_974116] dose.  
 
[IP_ADDRESS]  Retreatment E vents  
 
Twenty -one patients have received more than one course of Rituximab. The percentage of 
patients reporting any adverse event upon retreatment was similar to the percentage of patients 
reporting adverse events upon initial exposure. The following eve nts were reported more 
frequently in retreated participants : asthenia, throat irritation, flushing, tachycardia, anorexia, 
leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respi[INVESTIGATOR_715084], night sweats and pruritus.  
 
[IP_ADDRESS]  Hematologic Events  
 
In clinical trials, Grade 3 and 4 cytopenias were reported in 48% of patients treated with 
rituximab; these include: lymphopenia (40%), neutropenia (6%), leukopenia (4%), anemia (3%), 
and thrombocytopenia (2%).  The median duration of lymphopenia was 14 days (range, 1 to 588 
days) and of neutropenia was 13 days (range, 2 to 116 days).  A single occurrence of transient 
aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following 
rituximab therapy were reporte d.  
 
In addition, there have been a limited number of post marketing reports of prolonged 
pancytopenia, marrow hypoplasia, and late onset neutropenia (defined as occurring [ADDRESS_974117] dose of rituximab ) in patients with hematologic malignancies.   In reported cases of late 
onset neutropenia (NCI -CTC Grade 3 and 4), the median duration of neutropenia was 10 days 
(range 3 to 148 days). Documented resolution of the neutropenia was described in approximately 
one-half of the reported cases; of those wi th documented recovery, approximately half r eceived 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
27 growth factor support. In the remaining cases, information on resolution was not provided.  More 
than half of the reported cases of delayed onset neutropenia occurred in patients who had 
undergone prior a utologous bone marrow transplantation.  In an adequately designed, controlled, 
clinical trial, the reported incidence of NCI -CTC Grade 3 and 4 neutropenia was higher in 
patients receiving rituximab in combination with fludarabine as compared to those recei ving 
fludarabine alone (76% [39/51] vs. 39% [21/53]).  
 
[IP_ADDRESS]  Cardiopulmonary Events  
 
Patients with pre -existing cardiac conditions, including arrhythmia and angina have had 
recurrences of these cardiac events during rituximab infusions. Four patients develope d 
arrhythmias during rituximab infusion. One of the four discontinued treatment related incidence 
was because of ventricular tachycardia and supraventricular tachycardia. The other three 
patients experienced trigeminy (1) and irregular pulse (2) and did no t require discontinuation of 
therapy. Angina was reported during infusion and myocardial infarction occurred [ADDRESS_974118] infusion.  
 
[IP_ADDRESS]  Potential for fatal infusion reacti ons  
 
In post marketing studies, rare events of tumor lysis syndrome have been reported in patients 
who had a high number of circulating malignant cells (>25,000/ul), with a rapid reduction in 
tumor volume, renal insufficiency, hyperkalemia, hypocalcemia, hyperuricemia, and 
hyperphosphatemia noted in these patients. For additional details, and updates see current 
rituximab package insert. In rare cases, severe and fatal cardiopulmonary events, including 
hypoxia, pulmonary infiltrates, acute respi[INVESTIGATOR_104293], myocardial infarction, and 
cardiogenic shock, have occurred. Nearly all -fatal infusion -related events occurred in 
association with the first infusion.  
 
[IP_ADDRESS]  Prevention and management of abrupt increases in serum IgM and viscosity following  
Rituximab use in patents with WM.  
 
Abrupt and paradoxical increases in IgM levels have been reported with the use of rituximab in 
patients with WM, which may aggravate hyperviscosity and contribute to hyperviscosity related 
symptoms. Plasmapheresis is strongly encouraged for those patients  at increased risk for 
hyperviscosity.  Rituximab will also be omitted for Cycles 1 and/or 2 as necessary  and at the 
discretion of the Principal Investigator  [INVESTIGATOR_715085].  
 
2.1.3  Dexamethasone  
 
[IP_ADDRESS]  Intravenous Dexamethas one 
 
Each mL of clear, colorless sterile solution contains: dexamethasone sodium phosphate 
equivalent to dexamethasone phosphate 4 mg (equal to 3.33 mg of dexamethasone or roughly 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
28 about 100 mg of hydrocortisone). Non -medicinal ingredients: creatinine, sodi um citrate, sodium 
hydroxide (to adjust pH) and water for injection with sodium bisulfite, methylparaben, and 
propylparaben are added as preservatives.  
 
[IP_ADDRESS]  Oral Dexamethasone  
 
Dexamethasone is commercially available as tablets for oral administration in foll owing 
potencies: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, and 6 mg. Inactive ingredients 
are calcium phosphate, lactose, magnesium stearate, and starch.  
 
In the unlikely event of a drug supply interruption, oral dexamethasone will be substituted  
for IV dexamethasone at same dose used for intravenous administration.  
 
[IP_ADDRESS]  Contra indications for Dexamethasone therapy  
 
Dexamethasone will be omitted from therapy  while on study  in the following 
circumstances:  
• History of tuberculosis or other granulomatous disease;  
• Systemic fungal infection;  
• History of or development of uncontrollable steroid related glucose intolerance;  
• History of or development of steroid related hypersensitivity;  
• Intolerance due to gastric and duodenal ulcers despi[INVESTIGATOR_715086].  
• Recipi[INVESTIGATOR_22874] a live virus vaccine within 30 days.  
• Pregnancy and lactation.  
• Development of moderate to severe acute infections.  
 
In the event dexamethasone is omitted, p atients will not be removed from study treatment, and 
will continue to receive all other intended therapy on study.  
 
[IP_ADDRESS]  Drug -Interactions for Dexamethasone  
 
The following drug interactions with dexamethasone have been reported:  
• Concurrent administration of dexamethasone with thiazides or furosemide may cause 
excessive potassium loss.  
• Dexamethasone may decrease the effect of anti -muscarinic drugs.  
• Dexamethasone may increase the incidence of gastro -intestinal ulceration when 
administered concurrently with non -steroidal anti -inflammatory drugs.  
• Barbiturates, phenytoin, rifampi[INVESTIGATOR_2513], ephedrine, may enhance the metabolism clearance of 
corticosteroids and reduce the effects of dexamethasone.  
• Dexamethasone decreases the serum concentration of salicylates.  
• Response to anticoagulants may be altered by [CONTACT_149618].  
 
[IP_ADDRESS] Adverse Events with Dexamethasone  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
29 Fluid and electrolyte disturbances : sodium retention; fluid retention; congestive heart failure in 
susceptible patients; potassium loss; hypokalemic alkalosis; hypertension; hypotension or shock -
like reaction.  
 
Musculoske letal: muscle weakness; steroid myopathy; loss of muscle mass; osteoporosis; 
vertebral compression fractures; aseptic necrosis of femoral and humeral heads; pathologic 
fracture of long bones; tendon rupture.  
 
Gastrointestinal:  peptic ulcer with possible s ubsequent perforation and hemorrhage; perforation 
of the small and large bowel, particularly in patients with inflammatory bowel disease; 
pancreatitis; abdominal distention; ulcerative esophagitis.  
 
Dermatologic:  impaired wound healing; thin fragile skin;  petechiae and ecchymoses; erythema; 
increased sweating; may suppress reactions to skin tests, burning or tingling, especially in the 
perineal area (after i.v. injection), other cutaneous reactions such as allergic dermatitis, urticaria, 
angioneurotic edem a.  
 
Neurological: convulsions ; increased intracranial pressure with papi[INVESTIGATOR_044] (pseudotumor 
cerebri) usually after treatment; vertigo; headache; psychic disturbances.  
 
Endocrine:  menstrual irregularities; development of cushingoid state; suppression of growth in 
children; secondary adrenocortical and pi[INVESTIGATOR_80567], particularly in times of stress, 
as in trauma, surgery or illness; decreased carbohydrate tolerance; manifestations of latent 
diabetes mellitus; increased requirements for insulin  or oral hypoglycemic agents in diabetes; 
hirsutism.  
 
Ophthalmic:  posterior subcapsular cataracts; increased intraocular pressure; glaucoma; 
exophthalmos; retinopathy of prematurity.  
 
Cardiovascular:  myocardial rupture following recent myocardial infarction; hypertrophic 
cardiomyopat hy in low birth weight infants.  
 
Metabolic:  negative nitrogen ba lance due to protein catabolism.  
 
Other:  anaphylactoid or hypersensitivity reactions, thromboembolism, weig ht gain, increased 
appetite, nausea, malaise, hiccups.  
 
The following additional adverse reactions are related to parenteral corticosteroid therapy: rare 
instances of blindness associated with intralesional therapy around the face and head; 
hyperpi[INVESTIGATOR_715087]; s.c. and cutaneous atrophy; sterile abscess; post 
injection flare (following intra -articular use); Charcot -like arthropathy.  
 
2.2Study Disease  
 
WM is a rare B -cell lymphoproliferative disorder characterized by [CONTACT_403443] -producing lymphoplasmacytic cells. The disease was first reported by [CONTACT_594214]öm, 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
30 who described two patients with a high level of macroglobulin, i.e.  pentameric immunoglobulin 
M (IgM), marked hyperviscosity, typi[INVESTIGATOR_715088] (Waldenström 1944). Such malignant cells accumulate in the bone marrow, liver, 
spleen and lymph nodes. WM is diagnosed by [CONTACT_941] p resence of lymphoplasmacytic cells in the 
bone marrow and an IgM monoclonal spi[INVESTIGATOR_2531] (M -spi[INVESTIGATOR_2531]) identified in a serum protein 
electrophoresis (SPEP) (Ow en 2003 ). The incidence of WM in the [LOCATION_002] (US) is 
approximately 3 per million persons per year acco unting for 1000 -1500 new cases per year. The 
clinical course of WM is variable and although patients might experience an overall survival 
(OS) measured in decades, WM remains incurable with current therapeutic regimens. Hence, the 
disease course is charact erized by [CONTACT_715112], each harder to treat than the previous one. 
Additionally, many of the disabling symptoms associated with the disease, such as 
hyperviscosity, fatigue, anemia and/or neuropathy, can be exacerbated by [CONTACT_715113]. Hence, 
the car eful evaluation of agents with novel mechanisms of action is needed to improve the 
quality of life (QOL), and response and survival rates in patients with WM.  
 
2.3Rationale  
 
Despi[INVESTIGATOR_715089], WM remains incurable and as such; novel therapeuti cs are 
needed. Among the first line treatment options for WM are oral alkylators such as chlorambucil, 
nucleoside analogues, rituximab, alone and in combination treatment, thalidomide, and 
bortezomib (Treon 2006; Dimopoulos 2008). The use of oral alkylator s and nucleoside 
analogues is associated with risk of myelodysplasia/acute leukemia, disease transformation and 
stem cell damage thereby [CONTACT_715114], particularly in younger stem cell eligible 
transplant patients (Treon 2009 a; Leleu 2009). Ri tuximab is an important therapeutic,  generating 
overall response rates in 30 -40% of patients. Among WM patients receiving rituximab as 
monotherapy, lower response rates have been observed in those patients with high serum IgM 
(>6,000 mg/dL) and beta -2 micr oglobulin (B2M) (>3.0 mg/L) levels, as well as homozygous 
expression of phenylalanine at amino acid position 158 on CD16 (Fc γRIIIA -158) (Treon 2005 a; 
Dimopoulos 2005; Treon 2005 b). Limiting the application of rituximab is an idiopathic IgM flare 
phenomenon , which can provoke symptomatic hyperviscosity, as well as symptomatic IgM 
related morbidity. Moreover, patients with WM appear to develop earlier intolerance to 
rituximab versus patients with other indolent lymphomas , which may be related to the frequent 
presence of auto -IgG antibodies in WM patients.  
 
Bortezomib (Velcade®) is active in WM. As a single agent in relapsed/refractory WM, overall 
response rates of 40 -60% have been reported. In combination with rituximab, higher response 
rates have been observ ed in relapsed/refractory or untreated patients (70 -80%). The combination 
of bortezomib with dexamethasone and rituximab (BDR) is particularly active as primary 
therapy in WM with 96% overall response rate, and VGPR or better categorical responses in 
35% o f patients. In a recent update at the 6th International Workshop on WM, the projected 
progression free survival for BDR was estimated at >56 months. An important limitation 
however to the use of bortezomib is the development of >grade 3 peripheral neuropat hy in 20 -
30% of patients using twice a week schedule of administration, and 5 -10% with once a week. 
However, CR rates are potentially lower (5% vs. 20%), and risk of rituximab related IgM flare 
higher (20% vs. 10%) with attenuation of bortezomib dose to on ce a week, versus twice a week. 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
31 (Treon 2009 b; Ghobrial 2010). As such, the identification of novel, neuropathy and stem cell 
sparing agents is an important goal for therapy of WM.  
 
We recently reported our experience with the combination of carfilzomib  (Kyprolis®), 
dexamethasone and rituximab (CaRD) in 31 proteasome -inhibitor - and rituximab -naïve patients 
with WM (Treon 2013). Carfilzomib was administered IV on days 1, 2, 8 and 9 every 3 weeks. 
The median IgM levels declined from 3,510 mg/dL to 1,876 mg /dL, and the median M -protein 
from 2.09 g/dL to 0.99 g/dL. Median hemoglobin levels improved from 10.6 g/dL to 12 g/dL. 
Bone marrow tumor burden decreased from a median of 60% to 10%. The ORR was 74% (1 CR, 
6 VGPR, 9 PR and 1 MR). The treatment was well to lerated with the only grade 3 or 4 AE of 
neutropenia (7%). Grade 1 peripheral neuropathy developed in 19% of the patients. There was no 
grade 2 or higher peripheral neuropathy.  
 
2.4Correlative Studies Background  
 
2.4.1 MYD88 L265P and CXCR4 -WHIM -like mutations , and  FcRIIIA -158 (CD16) 
polymorphisms  
 
One of the major advances in the field of WM has been the recent discovery of a recurrent 
genetic abnormality, the MYD88 L265P mutation (Treon 2012). Sanger sequencing detected 
such mutation in tumor samples from 49 out of 54 patients (91%) with WM. Interestingly, the 
mutation was not detected in normal cells from WM patients and B -cells from healthy donors, 
and was absent or rarely expressed in cells from patients with multiple myeloma or marginal 
zone lymphoma. Such fin ding has been independently validated in subsequent studies from Italy, 
[LOCATION_009] the [LOCATION_002] with prevalence rates ranging between 90 -100% (Varettoni 2013; 
Poulain 2013; Ondrejka 2013). More recently, allele -specific PCR assays have been developed to 
improve the sensitivity of detection of the mutation and the quantification of the MYD88 L265P 
mutation burden (Xu 2013).  
 
More recently, mutations in the CXC chemokine receptor 4 (CXCR4) gene were identified in 16 
out of 55 (29%) WM patients investigated (Cao 2012). CXCR4 mutations are the second most 
common mutations found in WM patients. Such mutations are similar to the ones seen in patients 
with WHIM syndrome, an autosomal dominant genetic disorder characterized by [CONTACT_433210], 
hypogammaglobulinemia, infecti ons and myelokathexis (Hunter 2013) conferring gain of 
function and decreased CXCR4 internalization. In preclinical and clinical studies, CXCR4 -
WHIM mutations have been associated with lower responses to Bruton tyrosine kinase inhibitors 
(Cao 2013 ), but th eir significance in proteasome inhibitor -treated patients is not yet known.  
 
As part of these efforts, the impact of FcRIIIA -158 (CD16) polymorphisms as a predictor of 
categorical response in WM will be assessed. In previous studies by [CONTACT_715115], the pr esence of 
at least one valine at amino acid position 158 at Fc RIIIA (CD16) predicted for response to 
rituximab (Treon  2005 b). Patients displaying either valine/valine (V/V) or valine/phenylalanine 
(V/F) had a four -fold higher rate of response to single ag ent rituximab compared to patients 
displaying phenylalanine/phenylalanine (F/F) alone at Fc RIIIA -158. The impact of 
polymorphisms at Fc RIIIA -158 on response outcome has also been validated in other in dolent 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
32 lymphomas (Cartron 2002; Weng 2003), and has le ad to U.S. FDA clearance for such testing. 
The impact of Fc RIIIA -158 polymorphisms in predicting categorical response attainment in 
WM patients has recently been reported. Hunter et al demonstrated that better categorical 
responses (i.e. VGPR or better) w ere associated with V/V or V/F at Fc RIIIA -158 in patients 
who received combination therapy with ritu ximab (Treon 2011 ). As such, as part of these studies 
we will seek to determine the impact of Fc RIIIA -[ADDRESS_974119] meet the following criteria on screening examination to be eligible to 
participate in the study:  
 
Each patient must meet all of the following inclusion criteria to be enrolled in the study:  
1. Male or female patients [ADDRESS_974120] medical ca re, with the understanding that the patient may 
withdraw consent at any time without prejudice to future medical care.  
3. Female patients who:  
• Are postmenopausal for at least 1 year before the screening visit, OR  
• Are surgically sterile, OR  
• Are of childbearing potential,  
o agree to practice [ADDRESS_974121].  (Periodic abstinence [eg, calendar, ovulation, 
symptothermal, post -ovulation methods] and withdrawal are not acceptable 
methods of contraception.)  
Male patients, even if surgically sterilized  (ie, status post -vasectomy), must agree to one of 
the following:  
• Agree to practice effective barrier contraception during the entire study treatment 
period and through [ADDRESS_974122] dose of study drug, OR  
• Agree to practice true abstinence when th is is in line with the preferred and usual 
lifestyle of the subject.  (Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception.)  
4. Patients must have a clinicopathologica l diagnosis of WM (Owen 2003), with symptomatic 
disease meeting criteria for treatment using consensus panel criteria from the Second 
International Workshop on WM (Kyle 2003)  or serum IgM >6000 mg/dL , and measurable 
disease, defined as presence of immunogl obulin M (IgM) paraprotein with a minimum IgM 
level of >2 times the upper limit of normal.  
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974123] meet the following clinical laboratory criteria  
7. Absolute neutrophil count ( ANC) 1,000/mm3 and platelet count 75,000/mm3.  Platelet 
transfusions to help patients meet eligibility criteria are not allowed within 3 days before 
study enrollment.  
8. Total bilirubin 1.5  the upper limit of the normal range (ULN).  
9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  3  ULN.  
10. Calculated creatinine clearance  30 mL/min.  
 
3.2Exclusion Criteria  
 
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:  
1. Female patients who are lactating or have a positive serum pregnancy test during the 
screening period.  
2. Major surgery within [ADDRESS_974124] dose of MLN9708, with strong 
inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A 
(clarithromycin, telithromycin, itraconazole, voriconazole,  ketoconazole, nefazodone, 
posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepi[INVESTIGATOR_050], 
phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort.  
7. Known hepatitis B or C virus, or human immunodeficiency virus (HIV) i nfection.  
8. Any serious medical or psychiatric illness that could, in the investigator’s opi[INVESTIGATOR_1649], 
potentially interfere with the completion of treatment according to this protocol.  
9. Known allergy to any of the study medications, their analogues, or excipi[INVESTIGATOR_715090].  
10. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance 
of ixazomib including difficulty swallowing.  
11. Diagnosed or treated for another malignancy within [ADDRESS_974125] undergone complete resection.   Male patients with incid ental histological 
findings of prostate cancer (T1a or T1b using the TNM (tumor nodes, metasta sis) clinical 
staging system are not excluded.  
12. Participation in other clinical trials, including those with other investigational agents not 
included in this tria l, within 30 days  of the start of this trial and throughout the duration of 
this trial.  
 
 
4.REGISTRATION PROCEDURES  
 
4.1General Guidelines for DF/HCC and DF/PCC Institutions  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
34  
Institutions will register eligible participants in the Clinical Trials Management System (CTMS) 
OnCore.  Registration must occur prior to the initiation of therapy. Any participant not 
registered to the protocol before treatment begins will be considered ineligible and 
registration will be denied.  
 
An investigator  will confirm eligibili ty criteria and complete the protocol -specific eligibility 
checklist.  
  
Following registration, participants may begin protocol treatment. Issues that would cause 
treatment delays should be discussed with the Principal Investigator. If a participant does n ot 
receive protocol therapy following registration, the participant’s registration on the study must be 
canceled. Registration cancellations must be made in OnCore as soon as possible.  
 
4.2Registration Process  for DF/HCC and DF/PCC Institutions  
 
 
5.TREATMENT PLAN    
 
Treatment will be administered on an outpatient  or inpatient  basis. Expected toxicities and 
potential risks as well as dose modifications for ixazomib , rituximab, and dexamethasone are 
described in Section 6 (Expected Toxicities and Dosing Delays/D ose Modification). No 
investigational or commercial agents or therapi[INVESTIGATOR_163854]’s malignancy.  
 
IDR  Induction Phase  
Agent   Premedications  Dose  Route  Schedule  Cycle 
Length  
Dexamethasone  None  20 mg  IV or PO  Days 1, 8, 15  
Before 
ixazomib and 
rituximab  Every 4 
weeks  for 
Cycles 1 -6  
 
Rituximab 
omitted 
from 
cycle s 1 
and 2  Ixazomib  None 4 mg  PO Days 1, 8 15  
After 
dexamethasone  
Rituximab  Diphenhydramine  
25-50 mg PO /IV 
Acetaminophen  
650-1000 mg PO 
Famotidine 20mg IV  375 mg/m2 IV infusion  Day [ADDRESS_974126]  Maintenance Phase  
Agent  Premedication s Dose  Route  Schedule  Cycle 
Length  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
35 Dexamethasone  None  20 mg   
IV or PO  Day 1 , 8, and 15  
Before Ixazomib  
and Rituximab  
Every  8 
weeks +/ - 2 
weeks for 
Cycles 1 -6 Ixazomib  None  4 mg  PO Day 1 , 8, and 15  
After 
Dexamethasone  
Rituximab  Diphenhydramine  
25-50 mg PO/IV  
Acetaminophen  
650-1000 mg PO  
Famotidine 20mg IV  375 mg/m2 IV infusion   Day 1  
 After Ixazomib  
 
5.1Pre-Medication  
   
5.1.1 Rituximab  
 
To prevent infusion related or hypersensitivity reactions from occurring during infusion of 
rituximab, premedication consisting of diphenhydramine 25 -50 mg PO/IV, and Acetaminophen 
650-1000 mg PO should be given  to patients prior to administr ation of all infusions of 
rituximab, unless the patient has an allergy to either medication. Since transient hypotension 
may occur during rituximab administration, consideration should be given to withholding anti -
hypertensive medications 12 hours prior to  rituximab infusion. Prophylactic anti -emetic therapy 
for rituximab is generally not necessary, but may used at the discretion of the treating physician.  
 
5.2Agent Administration   
 
5.2.1 Ixazomib  
 
[IP_ADDRESS] Form of Ixazomib  
 
All later phase studies are conducted with the Capsule formulation.  
Ixazomib  Capsules  
The ixazomib  drug product is provided in strengths of 4.0 -, 3.0-, and 2.3 -mg and 2.0 -, 0.5-, 
and 0.2 mg capsules as the active boronic acid. The different dose strengths are differentiated 
by [CONTACT_12701]:  
 
 
 
Dose Strength  Capsule Siz e Capsule Color  
4.0 mg  Size 4  Ivory  
3.0 mg  Size 3  Light gray  
2.3 mg  Size 2  Light pi[INVESTIGATOR_8745]  
2.0 mg  Size 2  Swedish orange  
0.5 mg  Size 3  Dark green  
0.2 mg  Size 4  White opaque  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
36  Ixazomib Capsules are individually packaged in foil -foil blisters with a paper backing for child 
resistance.  
 
For additional details, please see the ixazomib IB.  
 
[IP_ADDRESS] Hydration    
 
IV hydration is recommended prior to ixazomib  for Cycle [ADDRESS_974127] of 500 mL normal saline or other appropriate IV fluid  over 1 hour .  IV 
hydration in subsequent cycles will be at the discretion of the Principal Investigator.  
 
[IP_ADDRESS] Ixazomib  Administration  
 
Ixazomib  should be administered after dexamethasone  each and every cycle, unless 
dexamethasone is omitted . Please refer to section [IP_ADDRESS]. The order of administration 
should be dexamethasone followed by [CONTACT_715116].  
 
All protocol -specific criteria for administration of study drug must be met and documented before 
drug administration.  Study drug will be administered or dispensed only to eligible patients under 
the supervision of the investigator or identified sub -inves tigator(s).  Patients should be monitored 
for toxicity, as necessary, and doses of ixazomib  should be modified as needed to accommodate 
patient tolerance to treatment; this may include symptomatic treatment, dose interruptions, and 
adjustments of ixazomib  dose (see Section 6.2).  
 
Capsules of ixazomib  will also be referred to as study drug.  Study drug will be supplied by 
[CONTACT_20552] 2.3, 3.0 and 4.0 mg ixazomib . The prescribed administration of 
ixazomib  doses in this study is 4 mg ixazomib  PO once weekly (+/-3 days) on days 1, 8 and 15 
in a 28 -day cycle during induction therapy, and once on day s 1, 8, and 15  in each maintenance 
cycle.  
 
Patients should be instructed to swallow ixazomib  capsules whole, with water, and not to break, 
chew, or open the capsules.  Study drug should be taken on an empty stomach (no food or drink) 
at least 1 hour before or 2  hours after a meal.  Each capsule should be swallowed separately with 
a sip of water.  A total of approximately 8 ounces (240 mL) of water should b e taken with the 
capsules.   
 
Missed doses can be taken as soon as the patient remembers if the next scheduled dose is [ADDRESS_974128] is an anti -cancer drug. Refer to the published institutional guidelines 
regarding the proper handling and disposal of anti -cancer age nts. 
 
Investigational ixazomib  (expi[INVESTIGATOR_20538]) should be destroyed on site according to the 
institution’s standard operating procedure.  Be sure to document removal and destruction on drug 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
37 accountability logs.  
 
5.2.2 Rituximab  
 
[IP_ADDRESS] Form of Rituximab  
 
Rituximab is supplied as a sterile, colorless, preservative free liquid concentrate for intravenous 
(IV) administration. Rituximab is supplied at a concentration of 10 mg/ml in either 100 mg (10 
mL) or 500 mg (50 mL) single -use vials. The product is formul ated for IV administration in 9 
mg/ml sodium chloride, 7.35 -mg/mL sodium citrate dehydrate, 0.7 mg/mL polysorbate 80, and 
sterile water for injection. The pH is adjusted to 6.5.  
 
[IP_ADDRESS] Method of Procurement for Rituximab     
 
Rituximab is a commercially available drug, which is approved by [CONTACT_941] U.S. Food and Drug 
Administration for use in patients with low g rade and follicular Non -Hodgkin  Lymphoma  
(NHL) . Use of this drug to treat patients with lymphoplasmacytic lymphoma (Waldenstrom's 
macroglobulinemia) is considere d to be a labeled indication  since it is included under the 
indolent NHL indication . Drug used in this study will be billed to patient and/or their third party 
payer (insurance).  
 
[IP_ADDRESS] Drug Stability and Compatibility of Rituximab  
 
Rituximab vials are stable a t 2-8 C. Vials of rituximab beyond expi[INVESTIGATOR_715091]. Rituximab vials should be protected from direct sunlight.  
 
[IP_ADDRESS] Preparation of Rituximab  
 
Rituximab is diluted to a final concentration of 1 to 4 mg/ml into an infusion bag containing 
either 0.9% sodium chloride USP or 5% dextrose in water USP. Rituximab solutions for 
infusion are stable at 2  to 8 C for [ADDRESS_974129] been 
reported.  
 
[IP_ADDRESS] Rituximab Pre -Treatment Medications  
 
To prevent infusion related or hypersensitivity reactions from occurring during infusion of 
rituximab, premedication consisting of diphenhydramine 25-50 mg IV, and a cetaminophe n 650 -
1000 mg PO should be give n to patients prior to administration of all infusions of rituximab, 
unless the patient has an allergy to either medication. Lower doses may be used if the p atient 
demonstrates tolerance. Since transient hypotension may occur  during rituximab administration, 
consideration should be given to withholding anti -hypertensive medications 12 hours prior to 
rituximab infusion. Prophylactic anti -emetic therapy for rituximab is generally not necessary, 
but may used at the discretion of the treating physician.  
 
[IP_ADDRESS] Rituximab Treatment Schedule and Administration  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
38  
Rituximab should be administered after ixazomib  on day 1 of induction cycles 3 -6 and 
maintenance cycles 1 -6. The order of administration should be dexamethasone followed by 
[CONTACT_715116].  Please see section [IP_ADDRESS].  
 
During the induction p hase Cycles 3 -6 on Day 1 and the ma intenance phase Cycles 1 -6 on Day 
1, Rituximab 375 mg/m2 IV is to be administered at an initial rate of 50 mg/hour for the first 
hour then escalate  the rate in 50 mg/ hours increments  approximately  every 30 minutes, to a 
maximum of 400 mg/hour. If h ypersensitivity or an infusion -related event develops such as 
T>101.3, mucosal edema, or a >30mm Hg decrease in SBP, interrupt the infusion, administer 
hypersensitivity rescue medications. When symptoms have resolved, the infusion can continue at 
one-half the previous rate and escalate in 50 mg/hr increments approximately each half hour, as 
tolerated. The infusion may be discontinued early at the discretion  of the treating investigator.   
For patients who have toler ated previous infusions without  hypersensitivity, subsequent 
infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr 
increments at approximately 30-minute interva ls, to a maximum of 400 mg/hr as tolerated.  
Alternatively, subsequent infusions can be administered at an initial rate of 20 percent of the total 
dose over 30 minutes, followed by [CONTACT_41757] 80 percent of the total dose over 60 minutes.   
 
Vital signs :  At the fi rst infusion, v ital signs should be checked and recorded at baseline , at the 
first rate change (usually at the approximately 1 hour point),  as needed for signs and s ymptoms 
of hypersensitivity reaction , and at the end of the infusion.  For subseque nt infusions,  vitals  
should be taken at baseline,  and as  needed for signs or symptoms of a reaction .  
 
[IP_ADDRESS] First Infusion of Rituximab  
 
The rituximab solution for infusion should be administered intravenously at an initial rate of 50 
mg/hr. Rituximab should not be mixed or diluted with other drugs. If hypersensitivity or infusion 
related events do not occur, the infusion can be escalated in 50 mg/hr increments  approximately  
every 30 minutes, to a maximum of 400 mg/hr. If hypersensitivity or an infusion -relate d event 
develops,  such as, T>101.3, mucosal edema, or a >30mm Hg decrease in SBP interrupt the 
infusion, administer hypersensitivity rescue medications. When symptoms have resolved, the 
infusion can continue at one -half the previous rate and escalate in 50  mg/hr increments each half 
hour, as tolerated.  
 
[IP_ADDRESS] Subsequent Rituximab infusions  
 
Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and 
increased by 100 mg/hr increments at approximately 30-minute intervals, to a maximum of  400 
mg/hr as tolerated. Rituximab is administered intravenously. Alternatively, subsequent 
infusions can be administered at an initial rate of 20 percent of the total dose over 30 minutes, 
followed by [CONTACT_41757] 80 percent of the total dose over 60 min utes.  To prevent infusion 
related or hypersensitivity events, Rituximab is not to be administered as an intravenous 
push or bolus.   
 
[IP_ADDRESS] Modification of Rate for Infusion of Rituximab  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
39  
In the event that patients develop an infusion related or hypersensitivity  reaction to rituximab 
then the rate of drug administration is altered as described above. The total dose administered 
remains the same in such cases. In the event of serious or life threatening reactions, the infusion 
should be terminated and such adverse  events reported.  In the event of serious or life threatening 
events attributed to rituximab, patients may permanently discontinue rituximab and remain on 
the study after consultation with the overall PI.  
 
5.2.3 Dexamethasone  
 
[IP_ADDRESS] Intravenous Dexamethasone  
 
Each mL of clear, colorless sterile solution contains: dexamethasone sodium phosphate 
equivalent to dexamethasone phosphate 4 mg (equal to 3.33 mg of dexamethasone or roughly 
about 100 mg of hydrocortisone). Non -medicinal ingredients: creatinine, sodium citrate , sodium 
hydroxide (to adjust pH) and water for injection with sodium bisulfite, methylparaben, and 
propylparaben are added as preservatives.  Store below 25°C. Do not freeze. Protect from light.  
 
[IP_ADDRESS] Contra indications and Drug interactions for Dexametha sone th erapy   
 
Refer to sections [IP_ADDRESS] and [IP_ADDRESS] for contra -indications and drug interactions with 
dexamethasone.  
 
[IP_ADDRESS] Dexamethasone Administration  
 
Dexamethasone should be administered before ixazomib  unless dexamethasone is omitted. 
Please refer to section [IP_ADDRESS] .  The order of administration should be dexamethasone 
followed by [CONTACT_715116].  Please see section [IP_ADDRESS].  
 
During the induction phase, Cycles 1 -6, Days 1, 8 and 15,  a total of 20 mg IV or PO 
dexamethasone will be administered before ixazomib . During the maintena nce phase, Cycles 1 -
8, Day 1,  a total of 20 mg IV or PO dexamethasone will be administered.    
 
20 mg oral dexamethasone may be substituted in the event of a drug supply shortage of IV 
dexamethasone  and on days 8 and 15 of induction and maintenance for dosing outside of clinic . 
Administration method will be documented.  
 
5.3General Concomitant Medication and Supportive Care Guidelines  
 
Concomitant medication is defined as any prescription or over -the-counter preparation including 
vitamins and supplements.  All required and optional/allowed concomitant medications must be 
recorded from screening through the end of the participant’s  study participation.  Any change in 
conc omitant medications must be recorded.  
 
5.3.[ADDRESS_974130] be recorded from screeni ng through the end of the 
participant’s  participation on trial.  
 
Green tea and/or green tea supplements are prohibited while  participating on trial.  
 
5.4Duration of Therapy  
 
Duration of therapy will depend on individual response, evidence of disease progressi on and 
tolerance. In the absence of treatment delays due to adverse events, treatment may continue 
for [ADDRESS_974131] ion therapy with 6  cycles of maintenance or until one of the following 
criteria applies:  
• Disease progression,  
• Intercurrent illness that  prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Participant demonstrates an inability or un willingness to comply with the 
regimen and/or documentation requirements  
• Participant decides to withdraw from the study, or  
• General or specific changes in the participant's condition render the participant  
unacceptable for further treatment in the opi[INVESTIGATOR_80021].  
 
5.5Duration of Follow Up  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
41 Participants will be followed every six months  (every 3 months preferred)  for two years 
after removal from study until next therapy or until death . Participants removed from study 
for unacceptable adverse events will be followed until resolution or stabilization of the adverse 
event.  
  
5.6Criteria for Removal from Study  
 
Particip ants will be removed from study when any of the criteria listed in Section 5. [ADDRESS_974132] be documented in the 
study -specific case report form (CRF). Alternative care options will be discussed with the 
participant.  
 
In the event of unusual or life -threatening complications, participating investigators must 
immediately notify the Principal Investigator, [CONTACT_715127] J. Castillo, Phone: 401 -489-4626 . 
 
6.EXPECTED TOXICITIES AND DOSING DELAYS/D OSE MODIFICATIONS  
 
Dose delays and modifications will be made using these recommendations. Toxicity assessments 
will be done using the CTEP Version 4 of the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.0, which is identified and lo cated on the CTEP website at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  
 
If possible, symptoms should be managed symptomatically. In the case of toxicity, appropriate 
medical treatment should be used (including antiemetic, antidiarrheal agents, etc.).  
 
All adverse events experienced by [CONTACT_137453], through the stud y and until the final study visit. Participants continuing to 
experience toxicity at the off study visit may be contact[CONTACT_221824].  
6.1Anticipated toxicities  
  
6.1.[ADDRESS_974133] frequent treatment -emergent adverse events (in at least 10% of patients), 
overall safety population (part 1)  
 
 
  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974134] frequent treatment -emergent adverse events (in at least 10% of patients), 
overall safety population (part 2)  
 
 
 
  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
44 Table 6 -2  Treatment -emergent rash events, overall safety population  (part 1)  
 
 
 
  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
45 Table 6 -2  Treatment -emergent rash events, overall safety population (part 2)  
 
 
 
6.1.2 Excluded Concomitant Medications and Procedures  
 
The following medications and procedures are prohibited during the study:  
• Systemic treatment with any of the following metabolizing enzyme inhibitors is not 
permitted during this study.  A drug -drug interaction [DDI] with a strong inhibitor 
would increase the ixazomib exposure and could lead to a higher probability of an 
AE). Strong inhibitors of CYP1A2:  fluvoxamine, enoxacin, ciprofloxacin . 
• Strong inhibitors of CYP3A:  clarithromycin, telithromycin, itraconazole, voriconazole, 
ketoconazole, nefazodone, an d posaconazole . Systemic treatment with any of the following 
metabolizing enzyme inducers should be avoided unless there is no appropriate alternative 
medication for the patient ’s use. Unlike with inhibitors, if there were to be a DDI with 
an inducer, ixaz omib exposure would be less; therefore, there would be a reduced 
chance of an AE.  However, there may be less chance for an antitumor effect, but that 
is not an absolute reason to be taken off ixazomib . 
• Strong CYP3A inducers:  rifampin, rifapentine, rifabu tin, carbamazepi[INVESTIGATOR_050], phenytoin, and 
phenobarbital  
• The dietary supplements St John’s wort and Ginkgo biloba are not permitted.  
The following procedures are prohibited during the study:  
• Any antineoplastic treatment with activity against WM  (i.e. high -dose ste roids, 
methotrexate, cyclophosphamide, etc.)  except for drugs in this treatment regimen.  
• Radiation therapy (note that, in general, the requirement for local radiation therapy 
indicates disease progression)  
• Platelet transfusions to help patients meet eligib ility criteria are not allowed within 
3 days prior to the blood draw that will confirm eligibility or any pre -dose CBC blood 
draws to guide dosing decisions (see Section [IP_ADDRESS])  
6.1.3 Permitted Concomitant Medications and Procedures (if applicable)  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
46  
The following medications and procedures are permitted during the study:  
• Antiemetics, including 5 -HT3 serotonin receptor antagonists, may be used at the discretion 
of the investigator.  
• Loperamide or other antidiarrheal should be used for symptomatic diarrhea a t discretion of 
the investigator. The dose and regimen will be according to institutional guidelines. IVF 
should be given to prevent volume depletion.  
• Growth factors (eg, granulocyte colony stimulating factor [G -CSF], granulocyte 
macrophage -colony stimulat ing factor [GM -CSF], recombinant erythropoietin) are 
permitted. Their use should follow published guidelines and/or institutional practice;. 
Erythropoietin will be allowed in this study. Their use should follow published guidelines 
and/or institutional pra ctice.  
• Patients should be transfused with red cells and platelets as clinically indicated and 
according to institutional guidelines.   Patients should not  have a CBC drawn to confirm 
eligibility or for on -treatment decisions (see section [IP_ADDRESS]: Dose Reductions for 
Hematologic Toxicities) less than [ADDRESS_974135]  a CBC drawn to confirm eligibility or for on -treatment decisions (see section 
[IP_ADDRESS]: Dose Reductions for Hematologic Toxicities)  more than 3 days following a 
platelet transfusion. If a patient receives a platelet  transfusion, then a 3-day wait  is 
recommended  for the CBC draw that would either confirm  eligibility or guide the decision 
with regards to the next dose (drug hold/dose reduce per Section [IP_ADDRESS]).  
• Antiviral therapy such as acyclovir may be administered if medically appropriate.  
• Concomitant treatment with bisphosphonates will be permitted, as  appropriate.  
• Patients who experience worsening neuropathy from baseline may be observed for 
recovery, and have dose reductions/delays as indicated in the protocol, and any supportive 
therapy or intervention may be initiated as appropriate at the discretio n of the investigator.  
• Supportive measures consistent with optimal patient care may be given throughout the 
study.  
6.1.4 Precautions and Restrictions  
 
• Fluid deficit should be corrected before initiation of treatment and during 
treatment.  
• Nonsteroidal anti -infla mmatory drugs (NSAIDs) should be avoided with impaired 
renal function given reported NSAID -induced renal failure in patients with 
decreased renal function.  
 
Pregnancy  
It is not known what effects ixazomib has on human pregnancy or development of the 
embryo or fetus.  Therefore, female patients participating in this study should avoid 
becoming pregnant, and male patients should avoid impregnating a female partner.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974136] meet 1 of the following:  
• Postmenopausal fo r at least 1 year before the screening visit, or 
• Surgically sterile, or 
• If they are of childbearing potential, agree to practice [ADDRESS_974137] dose of study drug, or   
• Agree to practice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject.  (Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods] and withdrawal are not acceptable method s 
of contraception.)  
 
Male patients, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the 
following:  
• Practice effective barrier contraception during the entire study treatment period 
and through [ADDRESS_974138] dose of stu dy drug, or 
• Agree to practice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject.  (Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods for the female partner] and withdrawal are 
not a cceptable methods of contraception.)  
6.1.5 Management of Clinical Events (if applicable)  
 
Adverse drug reactions such as thrombocytopenia, diarrhea, fatigue, nausea, vomiting, and 
rash have been associated with ixazomib treatment.  Management guidelines regardin g 
these events are outlined below.  Further details of management of ixazomib  AEs are 
described in Section [ADDRESS_974139] Risk of Reactivation of Herpes Infection  
Patients may be at an increased risk of infection including reactivation of herpes zoster and 
herpes simplex viruses.  Antiviral therapy such as acyclovir, valacyclovir, or other antivirals may 
be initiated as clinically indicated.  Other antivirals are also acceptable.  
 
Nausea and/or Vomiting  
Standard anti -emetics , including 5 -HT 3 antagonists, are recommended for emesis occurring upon 
treatment initiation; prophylactic anti -emetics may also be considered.  Dexamethasone should not 
be administered as an anti -emetic.  Fluid deficit should be corrected before initiation of study drug  
and during treatment . 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
48  
Diarrhea  
Prophylactic antidiarrheals will not be used in this protocol. However, diarrhea should be 
managed according to clinical practice, including the administration of antidiarrheals once 
infectious causes are excluded. Fluid int ake should be maintained to avoid dehydration. Fluid 
deficit should be corrected before initiation of treatment and during treatment.  
 
Erythematous Rash With or Without Pruritus  
As with bortezomib, rash with or without pruritus has been reported with ixazo mib, primarily at 
the higher doses tested and when given with agents where rash is an overlappi[INVESTIGATOR_5171].  The 
rash may range from limited erythematous areas, macular and/or small papular bumps that may 
or may not be pruritic over a few areas of the body , to a more generalized eruption that is 
predominately on the trunk or extremities.  Rash has been most commonly characterized as 
maculopapular or macular.  To date, when it does occur, rash is most commonly reported within 
the first 3 cycles of therapy.  The rash is often transient, self -limiting, and is typi[INVESTIGATOR_20539] 1 to 
2 in severity.  
Symptomatic measures such as antihistamines or corticosteroids (oral or topi[INVESTIGATOR_2855]) have been 
successfully used to manage rash and have been used prophylactically in subse quent cycles.  The 
use of a topi[INVESTIGATOR_2855], IV, or oral steroid (eg, prednisone ≤ 10 mg per day or equivalent) is permitted.  
Management of a Grade 3 rash may require intravenous antihistamines or corticosteroids.  
Administration of ixazomib (and/or other causati ve agent if given in combination) should be 
modified per protocol and re -initiated at a reduced level from where rash was noted (also, per 
protocol).   
In line with clinical practice, dermatology consult and biopsy of Grade 3 or higher rash or any 
SAE invo lving rash is recommended.  Prophylactic measures should also be considered if a 
patient has previously developed a rash (eg, using a thick, alcohol -free emollient cream on dry 
areas of the body or oral or topi[INVESTIGATOR_12669]).  A rare risk is Stevens -Johnson Syndrome, a 
severe and potentially life -threatening rash with skin peeling and mouth sores, which should be 
managed symptomatically according to standard medical practice.  Punch biopsies for 
histopathological analysis are encouraged at the discreti on of the investigator.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974140] clinical practice. Ixazomib 
administration should be modified as noted as per dose modification recommendations in the 
protocol when thrombocytopenia occurs (see Table 6 -2). Therapy can be reinitiated at a reduced 
level u pon recovery of platelet counts. A rare risk is thrombotic thrombocytopenic purpura 
(TTP), a rare blood disorder where blood clots form in small blood vessels throughout the body 
characterized by [CONTACT_12703], petechiae, fever, or possibly more serious  signs and 
symptoms. TTP should be managed symptomatically according to standard medical practice.  
 
Neutropenia  
Blood counts should be monitored regularly as outlined in the protocol with additional testing 
obtained according to standard clinical practice.   Neutropenia may be severe but has been 
manageable.  Growth factor support is not required but may be considered according to standard 
clinical practice.  Ixazomib administration should be modified as noted as per dose modification 
recommendations in the protocol when neutropenia occurs (see Table 6 -2).  Therapy can be 
reinitiated at a reduced level upon recovery of ANCs.  
 
Fluid Deficit  
Dehydration should be avoided since ixazomib may cause vomiting, diarrhea, and dehydration.  
Acute renal failure has been  reported in patients treated with ixazomib, commonly in the setting 
of the previously noted gastrointestinal toxicities and dehydration.  
Fluid deficit should be corrected before initiation of study drug and as needed during treatment 
to avoid dehydration.  
 
Hypotension  
Symptomatic hypotension and orthostatic hypotension with or without syncope have been 
reported with ixazomib.  Blood pressure should be closely monitored while the patient is on 
study treatment and fluid deficit should be corrected as needed, especially in  the setting of 
concomitant symptoms such as nausea, vomiting, diarrhea, or anorexia.  Patients taking 
medications and/or diuretics to manage their blood pressure (for either hypo - or hypertension) 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974141] clinical practice,  including considerations for dose 
adjustments of their concomitant medications during the course of the trial.  Fluid deficit should 
be corrected before initiation of study drug and as needed during treatment to avoid dehydration.  
Posterior Reversible Enc ephalopathy Syndrome  
One case of posterior reversible encephalopathy syndrome, which ultimately resolved, has been 
reported with ixazomib.  This condition is characterized by [CONTACT_12704], seizures and visual loss, as 
well as abrupt increase in blood pressure .  Diagnosis may be confirmed by [CONTACT_81789] (MRI).  If the syndrome is diagnosed or suspected, symptom -directed treatment should 
be maintained until the condition is reversed by [CONTACT_311359].  
Transver se Myelitis  
Transverse myelitis has also been reported with ixazomib. It is not known if ixazomib causes 
transverse myelitis; however, because it happened to a patient receiving ixazomib, the possibility 
that ixazomib may have contributed to transverse myelitis cannot be excluded.  
6.1.[ADDRESS_974142] for Rituximab  
 
Anticipated Drug Toxicities  
 
The following safety data on rituximab related adverse events has been compi[INVESTIGATOR_220752] 315 
patients who were treated in 5 single agent studies.  
 
Infusion Related Even ts 
 
Rituximab is associated with hypersensitivity reactions, which may respond to adjustments in the 
infusion rate. An infusion related symptom complex consisting of fever and chills/rigors 
occurred in the majority of patients during the first rituximab in fusion. Other frequent infusion 
related symptoms include nausea, urticaria, fatigue, headache, pruritus, bronchospasm, dyspnea, 
sensation of tongue or throat swelling (angioedema), rhinitis, vomiting, hypotension, flushing, 
and pain at disease sites. These  reactions have generally occurred within [ADDRESS_974143] infusion, and resolved with slowing or interruption of the rituximab infusion 
and with supportive care (IV saline, diphenhydramine, famotidine  or cimetidine, acetaminoph en, 
glucocorticoids). The incidence of infusion related events decreased from 80% (7% Grade 3/4) 
during the first infusion to approximately 40% (5% to 10% Grade 3/4) with subsequent 
infusions. Mild to moderate hypotension requiring interruption of rituxima b infusion with or 
without administration of IV saline occurred in 10% of patients. Isolated occurrences of severe 
reactions requiring epi[INVESTIGATOR_715092]. Angioedema was reported in 13% of p atients, and was serious in one patient. 
Bronchospasm occurred in 8% of patients; one quarter of these patients were treated with 
bronchodilators. A single report of bronchiolitis obliterans was noted.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
51  
Immunologic Events  
 
Rituximab induced B -cell depletio n in 70 to 80% of patients, and was associated with decreased 
serum immunoglobulins in a minority of patients. The incidence of infection does not appear to 
be increased. During the treatment period, 50 patients in the pi[INVESTIGATOR_715093] 68 infectious  
events; 6 (9%) were grade 3 in severity, and none were Grade 4 events. Of the 6 serious 
infectious events, none were associated with neutropenia. The serious bacterial events included 
sepsis due to Listeria (n=1), staphylococcal bacteremia (n=1), and poly microbial sepsis (n=1). In 
the post -treatment period ([ADDRESS_974144] dose), bacterial infections 
included sepsis (n=1); significant viral infections included herpes simplex infections (n=2) and 
herpes zoster (n=3). The following im mune serious adverse events have been reported to occur 
rarely (<0.1%) in patients following completion of rituximab infusions: arthritis, disorders of 
blood vessels (vasculitis, serum sickness and lupus -like syndrome), lung disorders including 
pleuritis a nd scarring of the lung (bronchiolitis obliterans), eye disorders (uveitis and optic 
neuritis), and severe bullous skin reactions (including toxic epi[INVESTIGATOR_715094]) 
that may result in fatal outcomes. Patients may have these symptoms alone  or in combination 
with rash and polyarthritis.  
 
Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death has been 
reported in some patients with hematologic malignancies treated with rituximab. The majority of 
patients rec eived rituximab in combination with chemotherapy. The median time to the diagnosis 
of hepatitis was approximately [ADDRESS_974145] rece ived more than one course of rituximab. The percentage of 
patients reporting any adverse event upon retreatment was similar to the percentage of patients 
reporting adverse events upon initial exposure. The following events were reported more 
frequently in retreated participants : asthenia, throat irritation, flushing, tachycardia, anorexia, 
leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respi[INVESTIGATOR_037], night sweats and pruritus.  
 
Hematologic Events  
 
In clinical trials, Grade 3 and 4 cytopenias were reported in 48% of patients treated with 
rituximab including: lymphopenia (40%), neutropenia (6%), leukopenia (4%), anemia (3%), and 
thrombocytopenia (2%). The median duration of lymphopenia was 14 days (range, 1 to 588 
days) and of neutropenia was 13 days (range, 2 to 116 days). A single occurrence of transient 
aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following 
rituximab therapy were reported.  
 
In addition, there have been a limited numbe r of post marketing reports of prolonged 
pancytopenia, marrow hypoplasia, and late onset neutropenia (defined as occurring [ADDRESS_974146] dose of rituximab ) in patients with hematologic malignancies. In reported cases of late 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
52 onset neutropenia (NCI -CTC Grade 3 and 4), the median duration of neutropenia was 10 days 
(range 3 to 148 days). Documented resolution of the neutropenia was described in approximately 
one-half of the reported cases; of those with documented recovery, approximately half receive d 
growth factor support. In the remaining cases, information on resolution was not provided. More 
than half of the reported cases of delayed onset neutropenia occurred in patients who had 
undergone prior autologous bone marrow transplantation. In an adequa tely designed, controlled, 
clinical trial, the reported incidence of NCI -CTC Grade 3 and 4 neutropenia was higher in 
patients receiving rituximab in combination with fludarabine as compared to those receiving 
fludarabine alone (76% [39/51] vs. 39% [21/53]) . 
 
Cardiopulmonary Events  
 
Patients with pre -existing cardiac conditions, including arrhythmia and angina have had 
recurrences of these cardiac events during rituximab infusions. Four patients developed 
arrhythmias during rituximab infusion. One of the fou r patients discontinued treatment because 
of ventricular tachycardia and supraventricular tachycardias. The other three patients 
experienced trigeminy (1) and irregular pulse (2) and did not require discontinuation of therapy. 
Angina was reported during in fusion and myocardial infarction occurred [ADDRESS_974147] been reported in patients 
who had a high number of circulating malignant cells (>25,000/ul), with a rapid reduction in 
tumor volume, renal insufficiency, hyperkalemia, hypocalcemia, hyperuricemia, and 
hyperphosphatemia noted in these patients. For add itional details, and updates see current 
rituximab package insert. In rare cases, severe and fatal cardiopulmonary events, including 
hypoxia, pulmonary infiltrates, acute respi[INVESTIGATOR_1505], myocardial infarction, and 
cardiogenic shock, have occ urred. Nearly all -fatal infusion -related events occurred in association 
with the first infusion.  
 
Prevention and management of abrupt increases in serum IgM and viscosity following  
Rituximab use in patients with Waldenström’s  macroglobulinemia  
 
Abrupt and paradoxical increases in IgM levels have been reported with the use of rituximab in 
patients with Waldenström’s  macroglobulenemia, which may aggravate hyperviscosity and 
contribute to hyperviscosity related symptoms. Plasmapheresis is strongly e ncouraged for those 
patients  at increased risk for hyperviscosity. Rituximab will be omitted for Cycles [ADDRESS_974148] for Dexamethasone  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
53 Fluid and electrolyte disturbances: sodium retention; fluid retention; congestive heart failure 
in susceptible patients; potassium loss; hypokalemic alkalosis; hypertension; hypotension or 
shock -like reaction.  
 
Musculoskeletal: muscle weakness; steroid myopathy; loss of muscle mass; osteoporosis; 
vertebral compression fractures; aseptic necro sis of femoral and humeral heads; pathologic 
fracture of long bones; tendon rupture.  
 
Gastrointestinal : peptic ulcer with possible subsequent perforation and hemorrhage; perforation 
of the small and large bowel, particularly in patients with inflammatory bowel disease; 
pancreatitis; abdominal distention; ulcerative esophagitis.  
 
Dermatologic : impaired wound healing; thin fragile skin; petechiae and ecchymoses; erythema; 
increased sweating; may suppress reactions to skin tests, burning or tingling, especial ly in the 
perineal area (after i.v. injection), other cutaneous reactions such as allergic dermatitis, urticaria, 
angioneurotic edema.  
 
Neurological : convulsions; increased intracranial pressure with papi[INVESTIGATOR_044] (pseudotumor 
cerebri) usually after treatmen t; vertigo; headache; psychic disturbances.  
 
Endocrine: menstrual irregularities; development of cushingoid state; suppression of growth in 
children; secondary adrenocortical and pi[INVESTIGATOR_80567], particularly in times of stress, 
as in trauma, su rgery or illness; decreased carbohydrate tolerance; manifestations of latent 
diabetes mellitus; increased requirements for insulin or oral hypoglycemic agents in diabetes; 
hirsutism.  
 
Ophthalmic: posterior subcapsular cataracts; increased intraocular press ure; glaucoma; 
exophthalmos; retinopathy of prematurity.  
 
Cardiovascular: myocardial rupture following recent myocardial infarction; hypertrophic 
cardiomyopathy in low birth weight infants.  
 
Metabolic: negative nitrogen balance due to protein catabolism.  
 
Other: anaphylactoid or hypersensitivity reactions, thromboembolism, weight gain, increased 
appetite, nausea, malaise, hiccups.  
 
The following additional adverse reactions are related to parenteral corticosteroid therapy: rare 
instances of blindness associ ated with intralesional therapy around the face and head; 
hyperpi[INVESTIGATOR_715095]; subcutaneous  and cutaneous atrophy; sterile abscess; 
post-injection flare (following intra -articular use); Charcot -like arthropathy.  
 
6.2Toxicity Management and D ose Modifications/Delays   
 
6.2.[ADDRESS_974149] meet the following criteria:  
 
• ANC must be ≥ 1,000/mm3.  
• Platelet count must be ≥ 75,000/mm3.  
• All other non -hematologic toxicity (except for alopecia) must have resolved to ≤ Grade 1 
or to the patient’s baseline condition  
 
Transfusion of blood products and G -CSF administration is not permissible on treatment day s to 
meet the above requirements.  If the patient fails to meet the above -cited criteria for initiation of 
the next cycle of treatment, dosing of ixazomib,  rituximab, and dexamethasone  should be 
delayed for [ADDRESS_974150] been met. If the patient continues to fail to meet the above -cited 
criteria, delay therapy and continue to re evaluate. The maximum delay before treatment should 
be discontinued will be 28 days  or at the discretion of the Principal Investigator.    
 
For dosing recommendations upon recovery, refer to Table 6 -2 and Table 6 -3. 
 
Table 6 -1 MLN908 Dose Adjustments  
 
Dose Level  Dose (mg)  
Starting Dose  4.0 mg  
-1 3.0 mg  
-2 2.3 mg  
-3 Discontinue  
 
[IP_ADDRESS] Dose Reductions for Hematologic Toxicities  
 
Dosage adjustments for hematologic toxicity are outlined in Table 6 -2. 
Table 6 -2    Ixazomib  Dose Adjustments for Hematologic Toxicities  
Ixazomib can be held for maximum of 28 days except at discretion of PI  
[INVESTIGATOR_715096] -Cycle Dose Modifications   
If platelet count  30  109/L or ANC ≤ 0.50 
 109/L on a ixazomib  dosing day (other 
than Day 1)  Ixazomib  dose should be withheld.   
Complete blood count (CBC) with 
differential should be repeated at least every 
other day until the ANC and/or platelet 
counts have exceeded the prespecified values 
(see Section 6.2.1) on at least 2 occasions.   
Upon recovery, ixazomib  may be reinitiated 
with 1 dose level reduction.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
55 Dosage adjustments for hematologic toxicity are outlined in Table 6 -2. 
Table 6 -2    Ixazomib  Dose Adjustments for Hematologic Toxicities  
Ixazomib can be held for maximum of 28 days except at discretion of PI  
[INVESTIGATOR_715097] > 2 weeks in the start of a 
subsequent cycle due to lack of toxicity 
recovery as defined in Section 6. 3.1.  
ANC < 1.0  109/L, platelet count < 75  
109/L, or other nonhematologic toxicities > 
Grade 1 or not to the patient’s baseline 
condition  Hold ixazomib  until resolution as per criteria 
Section 6.2.  
Upon recovery, reduce ixazomib  1 dose 
level.  
The maximum delay before treatment should 
be discontinu ed will be 28 days or at the 
discretion of the PI.  
Dose Modifications for Subsequent 
Treatment Cycles   
All hematologic toxicities  For hematologic toxicity that occurs during a 
cycle but recover in time for the start of the 
next cycle,:  
 If dose was reduc ed within the cycle, start 
the next cycle at that same dose.  
If due to toxicity timing, ie, after Day [ADDRESS_974151] severe toxicity.  
 
  
 
[IP_ADDRESS] Dose Reductions for Non -Hematologic Toxicities  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
56 Table 6 -3    Ixazomib  Treatment Modification (Delays, Reductions, and 
Discontinuations) Due to Adverse Events (Non -Hematologic Toxicities)  
Ixazomib can be held for maximum of 28 days except at discretion of PI  
[CONTACT_550189] (Severity)  Action on Study Drug  Further Considerations  
Peripheral Neuropathy:  
Grade 1 peripheral neuropathy   
• No action   
Grade 1 signs and symptoms:  
asymptomatic; without pain or loss 
of function; clinical or diagnostic 
observations only [14]  
 
 
New or worsening Grade 1 
peripheral neuropathy with pain or 
Grade 2  • Hold study drug until 
resolution to Grade ≤ 1 or 
baseline  Grade 2 signs and symptoms:  
Moderate symptoms; limiting 
instrumental activities of daily 
living (ADL) [14]  
 
 
New or worsening Grade 2 
peripheral neuropathy with pain or 
Grade 3 • Hold study drug until 
resolution to Grade ≤ 1 or 
baseline  
• Reduce study drug to next 
lower dose upon recovery  
 Grade 3 signs and symptoms:  
severe symptoms; limiting self -
care ADL; assistive device 
indicated [14]  
New or worsening Grade 4 
peripheral neuro pathy  • Discontinue study drug   
 
 
Grade 2 Rash  • Symptomatic 
recommendations as per 
section 6.[ADDRESS_974152] 
clinician may discuss 
considerations for dose 
modifications and symptom 
management.  
 
Grade 3 nonhematologic toxicity 
judged to be related to study drug   
• Hold study drug until 
resolution to Grade < 1 or 
baseline   
Symptomatic recommendations 
noted in Section 6.6  
If not recovered to 
< Grade 1 or baseline 
within 4 weeks  
 • Reduce study drug 1  to next 
lower dose upon return to 
< Grade 1 or  baseline   
Subsequent recurrence 
Grade 3 that does not 
recover to < Grade 1 or 
baseline within 4 weeks  • Hold study drug until 
resolution to Grade < 1 or 
baseline  
• Reduce study drug to next 
lower dose  Monitor closely, take appropriate 
medical precautions, a nd provide 
appropriate symptomatic care  
   
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
57 Table 6 -3    Ixazomib  Treatment Modification (Delays, Reductions, and 
Discontinuations) Due to Adverse Events (Non -Hematologic Toxicities)  
Ixazomib can be held for maximum of 28 days except at discretion of PI  
[CONTACT_550189] (Severity)  Action on Study Drug  Further Considerations  
Grade 4 nonhematologic toxicities 
judged to be related to study drug  • Consider permanently 
discontinuing study drug  Exceptions are cases in which the 
investigator determines the patient 
is obtaining a clinical benefit  
 
Once ixazomib is reduced for any toxicity, the dose may not be re -escalated.  
 
[IP_ADDRESS] Missed Doses  
 
Missed doses will not be replaced during a cycle.  If a participant misses more than 2 doses of 
any cycle for reasons other than toxicity, the participant will be discontinued.  
 
[IP_ADDRESS] Changes in Body Surface Area (BSA)   
 
Dose adjustments do not need to be made based on BSA changes.  
 
[IP_ADDRESS] Management of Adverse Events due to Rituximab  
 
In the event that patients experience a fever spi[INVESTIGATOR_2531] (>101o F), rigors, mucosal congestion or 
edema, or a decline in blood pressure (>30 mm systolic drop) during infusion with rituximab, the 
infusion should be temporarily discontinued and the patient observed. When the patient has 
recovered, the infusion should  be restarted at half  the previ ous rate. Treatment of infusion -related 
symptoms with additional IV diphenhydramine, acetaminophen, IV corticosteroids, IV 
cimetidine or famotidine  is recom mended. Additional treatment with bronchodilators or IV 
saline may be indicated. Medications for treatment of hypersensitivity reactions, such as 
epi[INVESTIGATOR_238], antihistamines, famotidine  or cimetidine, and corticosteroids should be available for 
immediate u se in the event of a reaction during administration. Infusions should be discontinued 
in the event of serious or life -threatening cardiac arrhythmias. Patients who develop clinically 
significant arrhythmias should undergo cardiac monitoring during and afte r subsequent infusions 
of rituximab. Patients with pre -existing cardiac conditions including arrhythmias and angina 
have had recurrences of these events during rituximab therapy and should be monitored 
throughout the infusion and immediate post -infusion pe riod. 
 
No dose reductions of rituximab will be permitted in this study.  However, for patients who 
experience toxicities, delay in whole or in part for rituximab will be permitted.  In the event a  
patient cannot receive their intended rituximab infusion due to an infusion related reaction or  
toxicity to rituximab, then their therapy may be delayed for up to [ADDRESS_974153] their rituximab omitted, but continue receiving  
therapy otherwise as per protocol.  Plasmapheresis is strongly encouraged for those patients at 
increased risk for hyperviscosity. Rituximab will be omitted for Cycles  1 and/or  2 in all patients . 
 
CBC and differential will be obtained regularly as indicated in study calendar. Erythropoietin 
and transfusion  support are permitted. Same day treatment with platelets is allowed as long as 
eligibility is met. Drug toxicities will be reported using common toxicity criteria.  
 
Carriers of hepatitis B should be closely monitored for clinical and laboratory signs of active 
HBV infection and for signs of hepatitis throughout their study participation. Any participant 
who develops ac tive HBV infection or hepatitis should not be treated with any further rituximab 
therapy.  
 
[IP_ADDRESS] Modification of Rate for Infusion of Rituximab  
 
In the event that patients develop an infusion related or hypersensitivity reaction to rituximab 
then the rate of dru g administration is altered as described above in “Management of Adverse 
Events due to rituximab”. The total dose administered remains the same in such cases. In the 
event of serious or life threatening reactions, the infusion should be terminated and such  adverse 
events reported . In the event of serious or life threatening events attributed to rituximab, patients 
may be removed from this study after consultation with the overall or institutional protocol 
chairperson.  
 
7.DRUG FORMULATION AND ADMINISTRATION  
 
7.1Ixazomib  
 
7.1.1 Description  
 
Research Name  [CONTACT_161767]9708  
Chemical Name  2,2'-{2-[(1R) -1-({[(2,5 -dichlorobenzoyl)amino]acetyl}amino) -3-
methylbutyl] -5-oxo-1,3,[ADDRESS_974154] -4,4-diyl}diacetic acid  
Common name  2,2'-{2-[(1R) -1-({[(2,5 -dichlorobenzoyl)amino]acetyl}amino) -3-
methylbutyl] -5-oxo-1,3,[ADDRESS_974155] -4,4-diyl}diacetic acid  
Proprietary Name  [CONTACT_715126]  1239908 -20-3 
Classification  Proteasome inhibitor ( as the boronic acid).  
Molecular Formula  C20H23BCl 2N2O9 
Molecular Weight  517.[ADDRESS_974156] 
been developed: 0.2 -, 0.5-, 2.0-, 2.3-, 3.0-, 4.0-, and 5.5 mg; each capsule strength has a uniqu e 
color. Dosage strength is stated as the active boronic acid (MLN2238). Ixazomib Capsules are 
individually packaged in foil -foil blisters with a paper backing for child resistance.  The study drug 
ixazomib  capsules will be provided by [CONTACT_20555].  The stud y drug will be labeled and handled 
as open -label material, and packaging labels will fulfill all requirements specified by [CONTACT_715117].   
 
7.1.3 Storage  
 
Ixazomib  capsules should be stored unopened at 2°C to 8°C (36°F -46°F).  The capsules are 
individua lly packaged in cold form foil -foil blisters in a child -resistant package.  The 2.[ADDRESS_974157] wallet.   The 
permissible storage condition excursion range is 8°C to 40 °C for a maximum period of 30 days; 
and from 0 -50°C for up to [ADDRESS_974158].  
 
Upon receipt at the investigative  site, ixazomib  should remain in the blister and carton provided 
until use or until drug is dispensed. The container should be stored at the investigative site 
refrigerated (36°F to 46°F, 2°C to 8°C). Ensure that the drug is used before the retest expi[INVESTIGATOR_4061] d ate 
provided by [CONTACT_20555]. Expi[INVESTIGATOR_20541].  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974159] 
daily dose configurations. Comprehensive instructions should be prov ided to the patient in order 
to ensure compliance with dosing procedures. Patients who are receiving take -home medication 
should be given only 1 cycle of medication at a time. Patients should be instructed to store the 
medication refrigerated (36°F to 46°F , 2°C to 8°C) for the duration of each cycle. Patients should 
be instructed to return their empty blister packs to the investigative site, rather than discarding 
them. Reconciliation will occur accordingly when the patient returns for their next cycle of t ake-
home medication. Any extreme in temperature should be reported as an excursion and should be 
dealt with on a case -by-case basis.  
 
Because ixazomib  is an investigational agent, it should be handled with due care. Patients should 
be instructed not to che w, break, or open capsules. In case of contact [CONTACT_12698], raising 
dust should be avoided during the clean -up operation. The product may be harmful by [CONTACT_12699], 
ingestion, or skin absorption. Gloves and protective clothing should be worn during  cleanup and 
return of broken capsules and powder to minimize skin contact.  
The area should be ventilated and the site washed with soap and water after material pi[INVESTIGATOR_9696] -up is 
complete . 
 
In case of contact [CONTACT_12700] (eg, from a broken capsule), skin shou ld be washed immediately 
with soap and copi[INVESTIGATOR_12666] [ADDRESS_974160] capsules.  
 
7.1.5 Availability  
 
The study drug ixazomib  capsules will be provided by [CONTACT_20555].  The study drug will be 
labeled and handled as open -label material, and packaging labels will fulfill all requirements 
specified by [CONTACT_20556].  
 
Ixazomib  capsules should be stored unopened at 2°C to 8°C  (36°F -46°F).  The capsules are 
individually packaged in cold form foil -foil blisters in a child -resistant package.    The capsules 
are individually packaged using cold -form foil -foil blisters that are in a child -resistant carton.  
There are 3  capsules  in each wallet/carton.  
 
7.1.[ADDRESS_974161] of the inventory and disposition of the agent (investigational or free of charge) using the 
NCI Drug Accountability Record or another comparable drug ac countability form. (See the 
CTEP website at http://ctep.cancer.gov/protocolDevelopment   for the “Policy and Guidelines for 
Accountability and Storage of Investigational Agents” or to obtain a copy of the drug 
accountability form.)  
 
Millennium Phar maceuticals  and the Pharmacy will maintain records of each shipment of 
investigational product.  The records will document shipment dates, batch numbers, and quantity 
of vials contained in the shipment.  Upon receipt of the investigational product, the designated 
recipi[INVESTIGATOR_715098] y site will inspect the shipment, verify the number and condition of the vials, 
and prepare an inventory or drug accountability record.  
 
Drug accountability records must be readily available for inspection by [CONTACT_715118].  
 
7.1.8 Destruction and Return  
 
Investigational ixazomib  (expi[INVESTIGATOR_20538]) should be destroyed on site according to the 
institution’s standard operating procedure.  Be sure to document removal and destruction on drug 
accoun tability logs.  
 
7.2Rituximab  
 
7.2.1 Description  
 
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed 
against the CD20 cell surface antigen. The antibody is an IgG kappa immunoglobulin 
containing murine light - and heavy -chain var iable region sequences and human constant region 
sequences. Rituximab is a composed of two heavy chains of 451 amino acids and two light 
chains of 213 amino acids (based on cDNA analysis) and has an approximate molecular weight 
of 145 kD. Rituximab has a b inding affinity for the CD20 antigen of approximately 8 nM. The 
chimeric anti -CD20 antibody is produced by [CONTACT_282466] (Chinese Hamster ovary) 
suspension culture in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not 
detectable in the final product. Rituximab is purified by [CONTACT_715111]. The purification process includes specific viral inactivation and removal 
procedures.  
 
Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and  death has 
been reported in some patients with hematologic malignancies treated with rituximab.  The 
majority of patients received rituximab in combination with chemotherapy.  The median time to 
the diagnosis of hepatitis was approximately [ADDRESS_974162] dose.  
 
7.2.2 Form  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
62 Rituximab is supplied as a sterile, colorless, preservative free liquid concentrate for intravenous 
(IV) administration. Rituximab is supplied at a concentration of 10 mg/ml  in either 100 mg (10 
mL) or 500 mg (50 mL) single -use vials. The product is formulated for IV administration in 
9mg/ml sodium chloride, 7.35 -mg/mL sodium citrate dehydrate, 0.7 mg/mL polysorbate 80, and 
sterile water for injection. The pH is adjusted to 6 .5. 
 
7.2.3 Storage and Stability  
 
Rituximab vials are stable at 2 -8 C. Vials of rituximab beyond expi[INVESTIGATOR_715091]. Rituximab vials should be protected from direct sunlight.  
 
7.2.4 Handling  
 
Rituximab is diluted to a final concentration of 1 to 4 mg/ml into an infusion bag containing 
either 0.9% sodium chloride USP or 5% dextrose in water USP. Rituximab solutions for 
infusion are stable at 2  to 8 C for [ADDRESS_974163] been 
reported.  
 
7.2.5 Availability  
 
Rituximab is commercially available.  
 
7.2.6 Administration  
 
Rituximab is administered intravenously. To prevent infusion related or hypersensitivity event s, 
rituximab is not to be administered as an intravenous push or bolus.  See section  [IP_ADDRESS] for 
details on administration of rituximab.  
 
7.3Dexamethasone  
 
7.3.1  Description  
 
Dexamethasone  is a potent synthetic member of the glucocorticoid class of steroid  hormones . It 
acts as an anti-inflammatory  and immunosuppressant . Its potency is about 20 -30 times that of 
hydrocortisone  and 4 -5 times of prednisone . 
 
Figure 7 -2 Structure of dexamethasone  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
63  
 
7.3.2 Form  
 
Each mL of clear, colorless sterile solution contains: dexamethasone sodium phosphate 
equivalent to dexamethasone phosphate 4 mg (equal to 3.33 mg of dexamethasone or roughly 
about 100 mg of hydrocortisone). Non -medicinal ingredients: creatinine, sodium citrate, sodium 
hydroxide (to adjust pH) and water for injection with sodium bisulfite, met hylparaben, and 
propylparaben are added as preservatives.  
 
7.3.3 Storage and Stability  
 
Store below 25°C. Do not freeze. Protect from light.  
 
7.3.4 Availability  
 
Dexamethasone is a commercially available agent.  
 
7.3.5 Administration  
 
Patients will receive dexamethasone 20 mg IV , with each infusion of ixazomib  and rituximab. 
Dexamethasone should be given prior to ixazomib and rituximab. The administration of IV 
Dexamethasone will suffice for steroid for premedication for rituximab.  20 mg oral 
dexamethasone may be substituted  in the event of a drug supply shortage of IV dexamethasone  
and on days 8 and 15 of induction and maintenance for dosing outside of clinic . Administration 
method will be documented.  
 
7.3.6 Contra indications for Dexamethasone therapy  
 
Dexamethasone will be omitte d from therapy in the following circumstances:  
• History of tuberculosis or other granulomatous disease  
• Systemic fungal infection  
• History of or development of uncontrollable steroid related glucose intolerance  
• History of or development of steroid related hyp ersensitivity  
• Intolerance due to gastric and duodenal ulcers despi[INVESTIGATOR_715099]  
• Recipi[INVESTIGATOR_22874] a live virus vaccine within 30 days  

 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
64 • Pregnancy and lactation  
• Development of moderate to severe acute infections  
 
In the ev ent dexamethasone is omitted, p atients will not be removed from study treatment and 
will continue to receive all other intended therapy on study.  
 
7.4Study compliance  
 
Study drug will be administered or dispensed only to eligible patients under the supervision of 
the investigator or identified sub -investigator(s).  The appropriate study personnel will maintain 
records of study drug receipt and dispensing.  
 
7.5Termination of Treatment and/or Study Participation  
Patients will be informed that they have the right to withdraw from the study at any time for any 
reason, without prejudice to their medical care.  The investigator also has the right to withdraw 
patients from the study for any of the following reasons:  
• Adverse event  
• Protocol violation  
• Lost to fo llow-up 
• Progressive disease  
• Study terminated  
• Other  
 
At the time of withdrawal, all study procedures outlined for the End of Study visit should be 
completed. The primary reason for patient’s withdrawal from the study should be recorded in the 
source docume nts and CRF.  
 
 
8.CORRELATIVE/SPECIAL STUDIES  
 
8.1Determination of MYD88 and CXCR4 mutational status  
 
The MYD88 L265P mutational analysis will be assessed by [CONTACT_265209] -specific PCR and CXCR4 
mutational analysis by [CONTACT_174960]. The Brigham & Women’s Hospi[INVESTIGATOR_715100]88 mutational analysis . The CXCR4 mutational 
analysis and Fc γRIIIA -158 polymorphisms analysis will be performed by [CONTACT_715119]öm’s Macroglobulinemia  Research Laboratory . 
  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
65 9.STUDY CALENDAR  
 
 Screening  
≤30 days 
from study 
entry  Induction Phase  
q28 days +/ - 3 Days*,**  Inter-phase 
Visit  
Within 4 
weeks +/ - 2 
weeks of  
completion of  
Cycle 6 of 
induction  Maintenance Phase  
(Beginning 8 weeks 
+/- 2 weeks after 
Induction C6D1)  
q 8 weeks +/ - 
2 weeks  Off Treatment  
Visit  
within 4 weeks 
+/- 2 weeks of 
completion of 
all treatment  or 
removal from 
trial Follow -up 
Q6 months 
+/- 2 weeks 
for 2 years6 
Cycles 1 and 2  Cycles 3 -6 Cycles 1 -6 
D1 D8 D15 D1 D88 D158 D1**  D8 D15 
Dexamethasone   X X X X X X  X X X   
Ixazomib   X X X X X X  X X X   
Rituximab      X    X     
Informed consent  X             
Physical exam  
(Ht, Wt, BSA, VS)  X X    
X   X X   X X 
History  X X      X X   X X 
Concurrent meds  X X   X   X X   X X 
ECOG Performance Status  X X   X   X X   X X 
CBC w/diff, platelets  X X X X X X X X X   X X 
Serum chemistry1,  X X X X X X X X X1   X X 
Coagulation Profile  
(PT, PTT, INR)  X             
Quantitative IgM, IgA, IgG  X X   X   X X   X X 
SPEP and immunofixation2 X X   X   X X   X X 
Beta-2-Microglobulin  X             
B-HCG3 X             
Hepatitis B and C Screening  X             
MYD88 L265P status bone 
marrow (PCR)  X       X    X  
MYD88 L265P status 
peripheral blood (qPCR)  X7             
CXCR4 mutational status 
(Sanger)  X             
Adverse event evaluation  X X   X   X X   X  
Neuropathy Assessment  X X   X   X X   X  
CT scan w/ contrast 
Chest/Abdomen/Pelvis5 X4       X5    X5  
Bone Marrow Biopsy and 
Aspi[INVESTIGATOR_1516]2  X4       X    X  
*: Peripheral Neuropathy questionnaire and l abs do not need to be repeated if Day [ADDRESS_974164] be reviewed prior to study drug administration and meet eligibility.  
**: For c riteria for administration of treatment see Section 6.2  
1: Comprehensive chemistry panel: Albumin, total bilirubin, BUN, creatinine, calcium, chloride, glucose, potassium, total pro tein, sodium, SGOT, 
SGPT, alkaline phosphatase, magnesium  
 
2: Bone Marrow Biopsy and Aspi[INVESTIGATOR_715101], Interphase visit, and Off -Treatment  Visit. May be Repeated at other time 
points to confirm a suspected complete remission and at the Principal Investigator’s discretion  
3: Serum pregnancy test for women of childbearing potential  
4: If done within 9 0 days of screening, this will not be required at the screening visit  
5: Repeat to assess disease response or confirm a suspected complete remission if participant had lymphadenopathy, hepatosplenomegaly, or an 
extramedullary mass at baseline  defined as ad enopathy >1.5 cm in any axis, and splenomegaly >15 cm in the craniocaudal axis.  
6. Follow -up visits will be required every 6 months +/ - [ADDRESS_974165] International 
Workshop on Waldenstrom’s macroglobulinemia (Kimby 2006 ; Treon 2011 ). 
 
For participants who undergo TPE (total plasmapheresis), IgM will be considered unevaluable 
for [ADDRESS_974166] -pheresis IgM 
values will not be considered as nadir values.    
 
When rituximab induced IgM flare is suspected, serum IgM response will be determined to be 
unevaluable by [CONTACT_715120].  
 
Complete Response (CR):  A complete response (CR) is defined as having resolution of all 
symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein 
by [CONTACT_5294], an d resolution of any adenopathy or splenomegaly. A near CR (nCR) is 
defined as fulfilling all CR criteria in the presence of positive immunofixation test for an IgM 
paraprotein.  
 
Very Good Partial Response (VGPR):  is defined as > 90% reduction in serum IgM l evels.   
 
Partial Response (PR):  Partial response (PR) is defined as achieving a >50% reduction in 
serum IgM levels.  
 
Minor Response (MR):  A minor response (MR) is defined 25 -49% reduction in serum IgM 
levels.  
                       
Progressive Disease (PD):  Progressive disease (PD) is defined as occurring when a greater than 
25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the 
lowest attained response value (except as specfied above) or progression of clinically signif icant 
disease related symptom(s). When PD is suspected on the basis of increasing serum IgM, repeat  
of these studies within 2 + 1 week(s) will be required to confirm  PD. 
 
Stable Disease (SD):  Stable disease is defined as having < 25% change in serum IgM levels, in 
the absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or 
symptoms of WM.  
 
10.2Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started , except in cases of TPE, specified in section 
10.1). The participant's best response assignment will depend on the achievement of both 
measurement and confirmation criteria.  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
67 10.3Duration of Response  
 
Duration of overall response : The duration of overall response is measured from the time 
measurement criteria are met for an objective response i.e. CR, PR or MR (whichever i s first 
recorded) until the first date that recurrence or PD is objectively documented, taking as 
reference for PD the smallest measurements recorded since the treatment started  (except in 
cases of TPE, specified in section 10.1) . 
 
Duration of overall comp lete response: The duration of overall CR is measured from the time 
measurement criteria are first met for CR until the first date that recurrent disease is 
objectively documented.  
 
Duration of stable disease : Stable disease is measured from the start of t he protocol treatment 
until the criteria for progression are met, taking as reference the smallest measurements recorded 
since the treatment started  (except in cases of TPE, specified in section 10.1) . 
 
10.4Time to Progression  
 
Time to Progression  (TTP ) is defined as the duration of time from start of treatment to time of 
disease progression  as defined in section 10.1 . Death from any cause or initiation of a new anti -
neoplastic therapy will also be considered a progression event.   
 
     10.5   Time to Next Therapy  
 
Time to Next Therapy (TNT) is defined as the duration from start of protocol treatment  to time 
of initiation of any new anti -neoplastic therapy, including radiation or intrathecal therapy.    
 
11.ADVERSE EVENT REPORTING REQUIREMENTS  
 
11.1Definitions  
 
 
11.1.1 Adverse Event (AE)  Definition  
 
Adverse event (AE) means any untoward medical occurrence in a patient or subject administered 
a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product whether or not it is related to the medicinal product.  
This includes any newly occurring event, or a previous condition that has increased in severity or 
frequency since the administration of study drug.  
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinuation or delay in treatment, dose modification, therapeutic intervention, or is 
considered by [CONTACT_2418] a clinically significant change from baseli ne.   
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
68 11.1.2 Serious adverse event (SAE)  Definition  
 
Serious AE (SAE) means any untoward medical occurrence that at any dose:  
• Results in death . 
• Is life-threatening  (refers to an AE in which the patient was at risk of death at the time of 
the event.  It does not refer to an event which hypothetically might have caused death if it 
were more severe).  
• Requires inpatient hospi[INVESTIGATOR_1324]  (see 
clarification in the paragraph below on planned hospi[INVESTIGATOR_602]).  
• Results in persistent or significant disability or incapacity . (Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions).  
• Is a congenital anomaly/birth defect . 
• Is a medically important event .  This refers to an AE that may not result in death, be 
immediately life threatening, or require hospi[INVESTIGATOR_059], but may be considered serious 
when, based on appropriate medical judgment, may jeopardize the patient, require 
medical or surgical interventi on to prevent [ADDRESS_974167] of an infectious agent.   Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse; any 
organism, virus, or infectious particle (eg, prion protein transmitting Transmissible 
Spongiform Encephalopathy), path ogenic or nonpathogenic, is considered an infectious 
agent.   
 
Clarification should be made between a serious AE (SAE) and an AE that is considered severe in 
intensity (Grade 3 or 4), because the terms serious and severe are NOT synonymous.  The 
general te rm severe is often used to describe the intensity (severity) of a specific event; the event 
itself, however, may be of relatively minor medical significance (such as a Grade 3 headache).  
This is NOT the same as serious, which is based on patient/event out come or action criteria 
described above, and is usually associated with events that pose a threat to a patient’s life or 
ability to function.  A severe AE (Grade 3 or 4) does not necessarily need to be considered 
serious.  For example, a white blood cell c ount of 1000/mm3 to less than 2000 is considered 
Grade 3 (severe) but may not be considered serious.  Seriousness (not intensity) serves as a guide 
for defining regulatory reporting obligations.  
 
 
11.1.3 Expectedness  
 
Adverse events can be “Expected” or “Unexpect ed.”  
 
[IP_ADDRESS] Expected adverse event  
 
Expected adverse events are those that have been previously identified as resulting from 
administration of the agent. For the purposes of this study, an adverse event is considered 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974168], the Investigator’s Brochure, the 
package insert or is included in the informed consent document as a potential risk.   
 
Refer to Section 6.1 for a listing of expected adverse events associated with the study 
agent(s).  
 
[IP_ADDRESS] Unexpected adverse ev ent 
  
For the purposes of this study, an adverse event is considered unexpected  when it varies in 
nature, intensity or frequency from information provided in the current adverse event list, the 
Investigator’s Brochure, the package insert or when it is not included in the informed consent 
document as a potential risk.   
 
11.1.4 Attribution  
 
Attribution is the relationship between an adverse event or serious adverse event and the study 
treatment. Attribution will be assigned as follows:  
 
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related  to the stu dy treatment.  
• Possible – The AE may be related  to the study treatment.  
• Unlikely - The AE is doubtfully related  to the study treatment.  
• Unrelated - The AE is clearly NOT related  to the study treatment.  
 
11.2Procedures for AE and SAE Recording and Reporting  
 
AEs may be spontaneously reported by [CONTACT_5363]/or in response to an open question from 
study personnel or revealed by [CONTACT_4171], physical examination, or other diagnostic 
procedures.  Any clinically relevant deterioration in laboratory assessments or  other clinical 
finding is considered an AE.  When possible, signs and symptoms indicating a common 
underlying pathology should be noted as one comprehensive event.  For serious AEs, the 
investigator must determine both the intensity of the event and the r elationship of the event to 
study drug administration. For serious pretreatment events, the investigator must determine both 
the intensity of the event and the relationship of the event to study procedures.  
 
AEs which are serious must be reported to Millen nium Pharmacovigilance (or designee) 
from the first dose of study drug through [ADDRESS_974169] of 
ixazomib .  Any SAE that occurs at any time after completion of ixazomib  treatment or after the 
designated follow -up period that the sponsor -investigator and/or sub -investigator considers to be 
related to any study drug must be reported to Millennium Pharmacovigilance (or designee).  In 
addition, new primary malignancies that occur during the follow -up periods must be reported, 
regardless of causality to study regimen, for a minimum of three years after the last dose of the 
investigational product, starting from the first dose of study drug. All new cases of primary 
malignancy must be reported to Millennium Pharmacovigilance (or designee).  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
70 Planned hospi[INVESTIGATOR_715102] (e.g., surgery was performed earlier or later than 
planned).  All SAEs should be monitored until they are resolved or are clearly determined to be 
due to a patient’s stable or chronic condition or intercurren t illness(es).  
 
Since this is an investigator -initiated study, the principal investigator [INVESTIGATOR_465751] J. Castillo, MD, also 
referred to as the sponsor -investigator, is responsible for reporting serious adverse events (SAEs) 
to any regulatory agency and to the sp onsor - investigator’s EC or IRB.    
 
Regardless of expectedness or causality, all SAEs (including serious pretreatment events) must 
also be reported to Millennium Pharmacovigilance:  
 
Fatal and Life Threatening SAEs within 24 hours of the sponsor -investigator’s observation or 
awareness of the event  
 
All other serious (non -fatal/non life threatening) events within 4 calendar days of the sponsor -
investigator’s observation or awareness of the event  
 
See below for contact [CONTACT_715121].   
The sponsor -investigator must fax or email the SAE Form per the timelines above.  A sample of 
an SAE Form will be provided. The SAE report must include at minimum:  
• Event term(s)  
• Serious criteria  
• Intensity of the event(s):  Sponsor -investigator’s or sub -investigator’s 
determination.   Intensity for each SAE, including any lab abnormalities, will 
be determined by [CONTACT_128751], as a 
guideline, whenever possible.   The crit eria are available online at 
http://ctep.cancer.gov/reporting/ctc.html . 
• Causality of the event(s): Sponsor -investigator’s or sub -investigator’s 
determination of the relationship of the event(s) to s tudy drug administration.  
 
Follow -up information on the SAE may be requested by [CONTACT_20555].    
 
Intensity for each SAE, including any lab abnormalities, will be determined by [CONTACT_207121], as a guideline, whenever possible.  The criteria are 
available online at http://ctep.cancer.gov/reporting/ctc.html.  
 
In the event that this is a multisite study, the sponsor -investigator is responsible to ensure that the 
SAE reports are sent to Millennium Pharmacovigilance (or des ignee) from all sites participating 
in the study.  Sub -investigators must report all SAEs to the sponsor -investigator so that the 
sponsor -investigator can meet his/her foregoing reporting obligations to the required regulatory 
agencies and to Millennium Ph armacovigilance, unless otherwise agreed between the sponsor -
investigator and sub -investigator(s).   
 
Relationship to all study drugs for each SAE will be determined by [CONTACT_9940] -
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
71 investigator by [CONTACT_91854]: Is there a reasonable possibility that the AE 
is associated with the study drug(s)?  
 
Sponsor -investigator must also provide Millennium Pharmacovigilance with a copy of all 
communications with applicable regulatory authorities related to the study product(s), as soo n as 
possible but no later than [ADDRESS_974170] Information  
 
Fax Number: 1 -[PHONE_4452]  
Email: [EMAIL_355]  
 
Suggested Reporting Form:   
• SAE Report Form (provided by [CONTACT_20555])  
• US FDA MedWatch 3500A:  
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm  
 
 
 
Procedures for Reporting Drug Exposure During Pregnancy and Birth Events  
 
If a woman becomes pregnant or suspects that she is pregnant while participating i n this study  or 
within [ADDRESS_974171] immediately fax a 
completed Pregnancy Form to the Millennium Department of Pharmacovigil ance or designee 
(see Section 8.2).  The pregnancy must be followed for the final pregnancy outcome.  
 
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, the sponsor -investigator must also immediate ly fax a completed Pregnancy Form to 
the Millennium Department of Pharmacovigilance or designee (see Section 8.2).  Every effort 
should be made to follow the pregnancy for the final pregnancy outcome.  
 
11.3Reporting to the Institutional Review Board (IRB)  
 
Investigative sites within DF/HCC will report all serious adverse events directly to the DFCI 
Office for Human Research Studies (OHRS).  
 
11.4Reporting to the Food and Drug Administration (FDA)  
 
The DF/HCC Overall Principal Investigator, as holder of the IND, will be responsible for all 
communication with the FDA. The DF/HCC Overall Principal Investigator [INVESTIGATOR_715103], regardless of the site of occurrence, any adverse event that is serio us, unexpected and 
reasonably related (i.e., possible, probable, definite) to the study treatment.  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
72 Unexpected fatal or life -threatening experiences associated with the use of the study treatment 
will be reported to FDA as soon as possible but in no event later than 7 calendar days after initial 
receipt of the information.  
 
All other serious unexpected experiences associated with the use of the study treatment will be 
reported to FDA as soon as possible but in no event later than 15 calendar days after init ial 
receipt of the information.  
   
Events will be reported to the FDA by [CONTACT_756] (1 -800-FDA -1088) or by [CONTACT_6791] (1 -800-FDA -
0178) using Form FDA 3500A (Mandatory Reporting Form for investigational agents) or FDA 
Form 3500 (Voluntary Reporting Form for commerc ial agents). Forms are available at 
http://www.fda.gov/medwatch/getforms.htm .  
 
11.5Reporting to Hospi[INVESTIGATOR_715104].  
 
11.6Pregnancy Reporting  
 
If a woman becomes pregnant or suspects that she  is pregnant while participating in this study, 
she must inform the investigator immediately and permanently discontinue study drug.  The 
sponsor -investigator must immediately fax a completed Pregnancy Form to the Millennium 
Department of Pharmacovigilance  or designee (see Section 11.2).  The pregnancy must be 
followed for the final pregnancy outcome.  
 
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, the sponsor -investigator must also immediately fax a completed Pregnancy Form to 
the Millennium Department of Pharmacovigilance or designee (see Section 11.2).  Every effort 
should be made to follow the pregnancy for the final pregnancy outcome.  
 
11.7Monitoring of Adverse Events and Period of Observation  
 
All adverse events, both serious and non -serious, and deaths that are encountered from initiation 
of study intervention, throughout the study, and within [ADDRESS_974172] to follow -up. The presence and resolution of AEs and SAEs (with dates) should be 
documented on the appropriate c ase report form and recorded in the participant’s medical record 
to facilitate source data verification.  
 
For some SAEs, the study sponsor  ([CONTACT_715127] J. Castillo ) or designee may follow -up by 
[CONTACT_756], fax, and/or monitoring visit to obtain additional ca se details deemed necessary to 
appropriately evaluate the SAE report (e.g., hospi[INVESTIGATOR_44458], consultant report, or 
autopsy report).  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
[ADDRESS_974173] -study event(s) that might reasonably 
be related to  participation in this study.  
 
11.[ADDRESS_974174] MedComm Solutions 
(see below) and report the event.  Whenever possible, the associated product should be 
maintained in accordance with the label instructions pending further guidance fr om a Millennium 
Quality representative.  
 
For Product Complaints,  
call MedComm Solutions at  
[PHONE_3715] (877 MPI [INVESTIGATOR_53308])  
(US and International)  
 
Product complaints in and of themselves are not AEs.  If a product complaint results in an SAE, 
an SAE form shoul d be completed and sent to Millennium Pharmacovigilance (refer to Section 
8.2). 
 
 
12.DATA AND SAFETY MONITORING  
 
12.1Data Reporting  
 
12.1.[ADDRESS_974175], manage, and monitor data for this study.  
 
12.1.2 Data Submission  
 
The schedule for completion and submission of case report forms (paper or electronic) to the 
QACT is as follows:  
 
Form  Submission Timeline  
Eligibility Checklist  Complete prior to registration with QACT  
On Study Form  Within [ADDRESS_974176] day of the cycle  
Response Assessment Form  Within 10 days of the completion of the 
cycle required for response evaluation  
Off Treatment/Off Study 
Form  Within 14 days of completing treatment or 
being taken off study for any reason  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
74 Follow up/Survival Form  Within 14 days of the protocol defined 
follow up visit date or call  
 
12.2Safety Meetings  
 
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity 
and accrual data from this trial. The committee is composed of clinical specialists with 
experience in oncology and who have no direct relationship with the study. Inf ormation that 
raises any questions about participant safety will be addressed with the Principal Investigator [INVESTIGATOR_16298].  
 
The DSMC will meet quarterly and/or more often if required to review toxicity and accrual data.  
Information to be provided to the committee may include:  up -to-date participant accrual; current 
dose level information; DLT information; all grade [ADDRESS_974177] been reported; summary of all deaths occurring within 30 days for Phase I or II protocols; 
for gene transfer protocols, summary of all deaths while being treated and during active follow -
up; any response information; a udit results, and a summary provided by [CONTACT_3476]. Other 
information (e.g. scans, laboratory values) will be provided upon request.  
 
12.3Monitoring  
 
Involvement in this study as a participating investigator implies acceptance of potential audits or 
inspections, including source data verification, by [CONTACT_116535]/HCC 
Overall Principal Investigator (or Protocol Chair) or DF/HCC. The purpose of these audits or 
inspections is to examine study -related activities and documents to determ ine whether these 
activities were conducted and data were recorded, analyzed, and accurately reported in 
accordance with the protocol, institutional policy, Good Clinical Practice (GCP), and any 
applicable regulatory requirements.  
 
All data will be monito red for timeliness of submission, completeness, and adherence to protocol 
requirements. Monitoring will begin at the time of participant registration and will continue 
during protocol performance and completion.  
 
 
13.REGULATORY CONSIDERATIONS  
 
13.1Protocol Review and Amendments  
 
This protocol, the proposed informed consent and all forms of participant information related 
to the study (e.g., advertisements used to recruit participants) and any other necessary 
documents must be submitted, reviewed and approved  by a properly constituted IRB 
governing each study location.  
 
Any changes made to the protocol must be submitted as amendments and must be approved 
by [CONTACT_14226]. Any changes in study conduct must be reported to the 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
75 IRB. The DF/HCC O verall Principal Investigator (or Protocol Chair) will disseminate 
protocol amendment information to all participating investigators.  
 
All decisions of the IRB concerning the conduct of the study must be made in writing.  
 
13.2Informed Consent  
 
All participants must be provided a consent form describing this study and providing 
sufficient information for participants to make an informed decision about their 
participation in this study. The formal consent of a participant, using the IRB approved 
conse nt form, must be obtained before the participant is involved in any study -related 
procedure. The consent form must be signed and dated by [CONTACT_163901]’s legally authorized representative, and by [CONTACT_98902]. The 
participant must be given a copy of the signed and dated consent document. The original 
signed copy of the consent document must be retained in the medical record or research file.  
 
13.3Ethics and Good Clinical Practice (GCP)  
 
This study is to be conducted acc ording to the following considerations, which represent 
good and sound research practice:  
• US Code of Federal Regulations (CFR) governing clinical study conduct and ethical 
principles that have their origin in the Declaration of Helsinki  
• Title 21 Part 50 – Protection of Human Subjects  
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr50_02.html   
• Title 21 Part 54 – Financial Disclosure by [CONTACT_137476].access.gpo.gov/nara/cfr/waisidx_02/21cfr54_02.html   
• Title 21 Part 56 – Institutional Review Boards 
www.access.gpo.gov/nara/ cfr/waisidx_02/21cfr56_02.html   
• Title 21 Part 312 – Investigational New Drug Application 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr312_02.html   
• State laws  
• DF/HCC research policies and procedures:  
http://www.dfhcc.harvard.edu/clinical -research -support/clinical -research -unit-cru/policies -
and-procedures/   
 
It is understood that deviations from the protocol should be avoided, except when necessary to 
eliminate an immediate hazard to a research participant. In such case, the deviation must be 
reported to the IRB according to the local reporti ng policy.  
 
13.4Study Documentation  
 
The investigator must prepare and maintain adequate and accurate case histories designed to 
record all observations and other data pertinent to the study for each research participant. This 
information enables the study to  be fully documented and the study data to be subsequently 
verified.  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
76  
Original source documents supporting entries in the case report forms include but are not limited 
to hospi[INVESTIGATOR_1097], clinical charts, laboratory and pharmacy records, recorded data fro m 
automated instruments, microfiches, photographic negatives, microfilm or magnetic media, 
and/or x -rays.  
 
13.5Records Retention  
 
All study -related documents must be retained for the maximum period required by [CONTACT_137477].  
 
13.6IND Annual Reports  
  
The sponsor  investigator or his designee will submit the annual report for this PI-initiated trial 
within 60 days of the IND anniversary date in accordance with 21 CFR 312. 33.  The data 
elements  that are to be submitted in the report  are provided in 21 CFR 312.33 .  The Annual 
Report should be filed in the study's Regulatory Binder.  
 
 
14.STATISTICAL CONSIDERATIONS  
 
14.1Study Design/Endpoints  
 
Following Fleming’s single phase approach and w ith a one -sided alpha set at 0.05 and beta at 0.20 
(80% power) assuming a null VGPR or better of 18% and a successful VGPR or better of 40% , 
we will need to accrue 23 participants.   In a previous study, the co mbination of bortezomib, 
rituximab and dexamethasone induced VGPR or better of 35% [22]. If at least [ADDRESS_974178] will 
warrant further testing in patients with WM. Accounting for 10% of non -evaluable patients, the 
total sample size will be [ADDRESS_974179] one adverse event wil l be 9 3% when the actual probability of this 
event is 10%. Counting 1 patient who was registered but never started, 27 patients were accrued 
to this study.  
 
 
14.2Populations for analysis   
 
The population for all safety analyses is the Safety Analysis Set (SAS ). All participants  who 
receive at least one dose of any test material during the study will be included in the SAS 
population and included in the safety analysis.  
 
Participants  will be included in the Full Analysis Set (FAS) for the primary assessment of  
efficacy. The FAS will include  those participants  who have measurable disease present at 
baseline, have received at least one cycle of therapy, and have had their disease re -
evaluated .   
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
77 The Per -Protocol Analysis Set (PPS) is defined as all participants  from the FAS set who 
complete the study and are deemed to be protocol -compliant. To be protocol -compliant, a 
participant must not have any major protocol deviations during the study period. Protocol 
deviations will be identified prior to database lock and will be listed in the clinical study report. 
The PPS will be used for a secondary assessment of efficacy endpoints.  
 
14.3Participant Disposition  
 
The total number of participants  screened, completed, and prematurely discontinued from the 
study will be summarized.  The reason for termination for all participants  who discontinued will 
also be presented.  A listing of participants  with major protocol deviations will also be presented . 
 
14.4Participants  Baseline Characteristics  
 
Descriptive summaries of demographic and baseline characteristics will be presented for all 
participants . 
 
14.5Exposure to Investigational Material  
 
Exposure to all test material will be tabulated by [CONTACT_715122], defined as 
number of days from day of first dose to day of last infusion. Total amount of investigational 
material taken will also be presented.  
 
14.6Safety Analysis  
 
Safety evaluations will be presented by [CONTACT_715123], intensity and 
type of adverse events (AEs).  
 
All AEs occurring on study will be listed in by -participant  data listings. A by -dose tabulation 
will be provided that enumerates AEs by [CONTACT_764].  Deaths, SAEs and events resulting 
in study discontinuation will be tabulated.  
 
14.7Efficacy Analyses  
 
Primary and secondary analyses will be performed in both the FAS and PPS populations and will 
include calculating the proportion of patients having an overall response (MR or better) and 
major response (CR or VG). Confidence intervals (95%) about these poi nt estimates will be 
presented. Time to progression (TTP) and time to next therapy (TNT) as defined in sections 10.4, 
and 10.5, respectively will be estimated using Kaplan and Meier methodology with median time 
plus 25th and 75th percentile time to progres sion free survival along with 95% confidence 
intervals being provided, as appropriate. In addition, landmark analysis for 2 and 4 year 
progression free survival will be performed.  
 
14.8Sample Size/Accrual Rate  
 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
78 Following Fleming’s single phase approach and w ith a one -sided alpha set at 0.05 and beta at 0.20 
(80% power) assuming a null VGPR or better of 18% and a successful VGPR or better of 40% , 
we will need to accrue 30 participants.   In a previous study, the combination of bortezomib, 
rituximab and dexamethas one induced VGPR or better of 35% [22]. If at least [ADDRESS_974180] will 
warrant further testing in patients with WM. Accounting for 10% of non -evaluable patients, t he 
total sample size will be [ADDRESS_974181] one adverse event will be 97% when the actual probability of this 
event is 10%.  
 
The accrual expectation is [ADDRESS_974182] of MYD88 and CXCR4  gene mutation s, and 
FcγRIIIA -158 polymorphisms  in predicting overall and categorical response to tr eatment, as well 
as progression -free survival , will be assessed by [CONTACT_715124] /poly morphism  type. If there are sufficient numbers in each category, appropriate 
inferential statistics may be performed.  These analyses would be considered exploratory in 
nature.  
 
14.[ADDRESS_974183] receive copi[INVESTIGATOR_18472] 
(at least fifteen working days for presentational materials and abstracts an d thirty working days 
for manuscripts). These requirements acknowledge Millennium Pharmaceuticals’ responsibility 
to provide peer input regarding the scientific content and conclusions of such publications or 
presentations.  Principal Investigator/Institut ion shall have the final authority to determine the 
scope and content of its publications, provided such authority shall be exercised with reasonable 
regard for the interests of Millennium Pharmaceuticals and, in accord with the trial contract and 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
79 shall no t permit disclosure of Millennium Pharmaceuticals’ confidential or proprietary 
information.  
 
 
16.REFERENCES  
 
1. Owen RG, Treon SP, Al -Katib A, et al. Clinicopathological definition of Waldenström’s 
Macroglobulinemia: consensus panel recommendations from the Sec ond International 
Workshop on Waldenström’s Macroglobulinemia. Semin Oncol 2003; 30: 110 -115. 
2. Waldenström J. Incipi[INVESTIGATOR_715105] "essential" hyperglobulinemia with 
fibrinogenopenia - A new syndrome? Acta Med Scand 1944; 117: [ADDRESS_974184] International Workshop on Waldenstrom’s Macroglobulinemia. Blood 2006; 
107:3442 -6.  
4. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations  from 
the fourth international workshop on Waldenstrom’s  macroglobulinemia. J Clin Oncol 2008; 
27:120 -6 
5. Treon SP. How I Treat Waldenstrom’s Macroglobulinemia. Blood 2009a; 114(12) :2375 -85.  
6. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus ben efit in the treatment of 
Waldenström's Macroglobulinemia patients with nucleoside analogue -based therapy. Clin 
Lymphoma Myeloma 2009 Mar;9(1):71 -3.  
7. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström’s 
Macroglobulinemia. Ann Oncol 2005a; 16:132 -8.  
8. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to 
rituximab in Waldenstrom’s macroglobulinemia. Clin Lymphoma 2005; 5:270 -2. 
9. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcγRIIIA ( CD16) receptor 
expression are associated with clinical responses to Rituximab in Waldenstrom’s 
Macroglobulinemia. J Clin Oncol 2005b; 23: 474 -81.  
10. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom’s 
Macroglobulinemia with Bortezomi b, Dexamethasone and Rituximab: Results of WMCTG 
Clinical Trial 05 -180. J Clin Oncol 2009b; 27(23):3830 -5.  
11. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in 
combination with rituximab in untreated patients with Waldenström M acroglobulinemia. Am 
J Hematol . 2010;85(9):670 -4. 
12. Treon SP, et al. Prospective phase II clinical trial of carfilzomib, rituximab and 
dexamethasone (CARD) in Waldenström’s Macroglobulinemia (WM) . ASH Annual Meeting 
abstract, 2013.  
13. Treon  SP, Xu L, Yang G, et  al. MYD88 L265P somatic mutation in Waldenström's 
macroglobulinemia.  N Engl J Med  2012 ; 367(9): 826 -33. 
14. Ondrejka SL, Lin JJ, Warden DW, et al. MYD88 L265P Somatic Mutation: Its Usefulness in 
the Differential Diagnosis of Bone Marrow Involvement by B -Cell Lymphoproliferative 
Disorders. Am J Clin Pathol. 2013 Sep;140(3):387 -94. 
15. Cartron G, Dacheux L, Salles G, Solal -Celigny P, Bardos P, Colombat P, Watier H.  
Therapeutic activity of humanized anti -CD20 monoclonal antibody and polymorphism in 
IgG Fc receptor Fc gamma RIIIA gene.  Blood. 2002; 99:754 -8. 
16. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom 
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
80 macroglobulinemia. Blood. 2013 May 30;121(22):4504 -11. 
17. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance o f the MYD88 
(L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid 
neoplasms. Blood. 2013 Mar 28;121(13):2522 -8. 
18. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, 
immunoglobulin M monoclonal gammopathy,  and other B -cell lymphoproliferative disorders 
using conventional and quantitative allele -specific polymerase chain reaction. Blood. 2013 
Mar 14;121(11):2051 -8. 
19. Cao Y, Xu L, Liu X, et al. Whole Genome Sequencing Identifies Recurring Somatic 
Mutations in t he C-Terminal Domain of CXCR4, Including a Gain of Function Mutation in 
Waldenstrom's Macroglobinemia. Blood  (ASH Annual Meeting Abstracts) 2012. 120: 
abstract 2715.  
20. Hunter Z, Xu L, Yang G, et al. Recurring activation mutations and somatic deletions reveal ed 
through whole genome sequencing in Waldenstrom’s Macroglobulinemia. Hematological 
Oncol. 2013 June; 31(1S): abstract 093.  
21. Weng WK, Levy R. Two Immunoglobulin G Fc receptor polymorphisms independently 
predict response to rituximab in patients with follic ular lymphoma. J Clin Oncol 2003; 
21:3940 -3947.  
22. Treon et al. The attainment of CR/VGPR is associated with significantly longer progression 
free survival in rituximab naïve WM patients undergoing rituximab based therapy, and is 
predicted by [CONTACT_715125]RIIIA -158. Br J Haematol, 2011.  
23. Kyle R, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in 
Waldenström's macroglobulinemia: consensus panel recommendations from the Second 
International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003; 30: 116-
20.  
24. Kimby E, Treon SP, Anagnostopoulos A. Dimopoulos M, Garcia -Sanz R et al. Update on 
recommendations for assessing response from the Third International Workshop 
onWaldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;  6(5):  380-3. 
 
 
  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
81  
17.APPENDICES  
 
Appendix A: Performance Status Criteria  
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Description  Percent  Description  
0 Normal activity. Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
1 Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or  
sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease.  
70 Cares for self, unable to carry on 
normal activity or to do active 
work.  
2 In bed < 50% of the time. 
Ambulatory and capable of  all self -
care, but unable to carry out any 
work activities. Up and about more 
than 50% of waking hours.  [ADDRESS_974185] of 
his/her needs.  
50 Requires considerable assistance 
and frequent medical care.  
3 In bed >50% of the time. Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care 
and assistance.  
30 Severely disabled, 
hospi[INVESTIGATOR_374]. Death 
not imminent.  
4 100% bedridden. Completely 
disabled. Cannot carry on any self -
care. Totally confined to bed or 
chair.  20 Very sick, hospi[INVESTIGATOR_373]. Death not imminent.  
10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  
5 Dead.  0 Dead.  
Source:  Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 
(6):649 -55. 
 
  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
   
82 Appendix B: IDR Neuropathy Assessment Questionnaire  
 
Patient Name:____________ __________   MRN______________     
 
Patient Signature:___________________   Date___________  
 
Please circle one (1) number to indicate how true each of the following statements has been 
for you in the past [ADDRESS_974186] trouble walking           0   1    2     3      4  
 
Adapted from “Neurotoxicity Assessment Tool” Millennium . Cella DF, Tulsky DS, Gary G et al. The functional assessment of cancer therapy (FACT) scale: 
development and validation of the general measure.  J Clin Onco l 1993:11(3):[ADDRESS_974187]/GOG -Ntx. Abstract 1751. 36th Annual Meeting of the American Society of Clinical  Oncology, May 2000, New Orleans, LA.  None     A little bit   Somewhat  Quite a bit   Very much  Screening/Off Study  
Induction/Maintenance  
Cycle_____  Day____  